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PREFACE 
Normal growth is the result of a very complex interac-
tion between nutritional and hormonal factors and the re-
sponsiveness of the target organs. This holds equally true 
for fetal and postnatal growth. 
Present knowledge about the hormonal control of fetal 
growth is briefly reviewed in chapter I. There are several 
indications, among which "experiments of nature", sug-
gesting that hormones do play an important growth promot-
ing role during fetal life. The presence of growth promot-
ing factors in the fetus has long since been recognized, 
and many attempts have been made to isolate the active fe-
tal factors. 
One of the hormones involved in the regulation of post-
natal growth is pituitary growth hormone (GH) or somato-
tropin. Although the hypothalamo-pituitary system rapidly 
develops notably early in fetal life and acromegalic values 
of GH are found in fetal serum, the role of GH during fetal 
growth is uncertain. In recent years, considerable atten-
tion has been focused on somatomedin (SM) or insulin-like 
growth factors (IGF), i.e., GH dependent, small molecular 
weight peptides with insulin-like activity, mediating the 
growth promoting actions of GH. It remains puzzling why 
during the pre- and perinatal period SM levels in serum or 
amniotic fluid, measured by various assay techniques, are 
unvariably very low. The presence, there-fore, of a specif-
ic embryonic SM has been postulated. 
SM circulates in plasma bound to macromolecular weight 
carrier or binding proteins. At least two forms (150-200,000 
and 40-50,000 MW) in postnatal plasma have been recognized. 
The precise function of these binding proteins is unclear. 
l 
In addition to being carrier proteins, they may play an 
important role in the regulation of the biological effects 
of circulating SM. 
This thesis study was undertaken in order to investigate 
the nature and biological behavior of a somatomedin binding 
protein1 identified in preterm amniotic fluid. 
In chapter II
1
the partial purification and characteri-
zation of a binding protein for SM (IGF-II) in human pre-
term amniotic fluid (AF) are described. This amniotic 
fluid binding protein (AFBP) inhibits the insulin- and SM-
like effects of IGF-II in various in vitro bioassays. It 
proved necessary to further purify this binding protein in 
order to perform not only additional characteriZation stud-
ies, but above all in order to raise a specific antibody, 
allowing detection and quantitation in various body fluids. 
In chapter III, an improved procedure is presented for 
the isolation of AFBP from preterrn amniotic fluid, with 
high speed gel filtration chromatography (HSGFC) and disc-
gel polyacrylamide gel electrophoresis as the final steps. 
In appendix 1, chapter III, the methodology of HSGFC, a 
recent advancement in protein purification, is given. 
As is outlined in chapter IV 1 an antibody against AFBP 
was raised in rabbits and the antiserum cleared of contam-
inating anti-albumin antibodies. Subsequently, a specific 
radioimmunoassay (RIA) was developed. AFBP values measured 
by RIA in preterm AF (16-20 weeks of gestation) were twice 
as high as in term AF. Following Sephadex G-200 chromato-
graphy of serum at pH 2.2 and pH 7.4, AFBP-RIA activity 
was identified only in fractions at Kav ~ 0.6, identical 
to the elution volume of labeled AFBP. 
In human fetal (20-22 weeks of gestation) and term cord 
serum, markedly elevated serum levels of AFBP were found 
2 
(chapter V). These contrasted with low IGF-I (SM-C) levels 
(measured in the same samples by RIA) and with decreased 
AFBP, but normal IGF-I/SM-C levels in serum of adults. In 
serum of children with GH deficiency, AFBP values were 
higher than in age-matched controls; they declined follow-
ing GH therapy. In these patients, SM values were below 
normal for age, generally showing an increase during GH 
treatment. AFBP shows a striking similarity to an unsatu-
rated SM bindinq protein, as described by Hintz {1981), 
Speculations regarding the regulatory mechanisms for 
AFBP and its physiological importance are discussed in 
chapter VI. 
The AFBP radioimmunoassay will facilitate a further elu-
cidation of the physiological importance of AFBP, which 
may contribute to the understanding of SM action in pre-
and postnatal growth. 
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CHAPTER I 
HORMONAL REGULATION OF FETAL GROWTH 
I.l. Introduction 
Normal fetal growth depends upon a complex interaction 
between nutritional and hormonal factors and the respon-
siveness of the target organs. These factors lie at the root 
of many well-known maternal, placental and fetal causes of 
intrauterine growth retardation. 
Several "experiments of nature" in humans suggest that 
hormones play an important growth promoting role during fe-
tal life, but not necessarily in the same way postnatally 
(Cheek ~tal., 1977). Some of the hormones indispensable for 
postna·tal growth, such as thyroid hormone and growth hor-
mone, do not appear to be so prenatally. For instance, in-
fants with complete thyroid hormone deficiency or. with prov-
en GH deficiency are of normal length at birth (Letarte et 
al., 1980; Cheek et al., 1977). Hyperinsulinernia or in-
creased sensitivity to insulin results in overgrowth. A 
well-known example is the infant of a diabetic mother (IDM) . 
Poor treatment of the insulin-dependent diabetic mother re-
sults in overgrowth of almost every tissue except the brain. 
These abnormalities disappear following good control of 
the maternal diabetes. Frequently, the infant producing an 
excess of insulin due to a tumor or nesidioblastosis, is 
clinically indistinguishable from the IDM. Increased num-
bers of insulin receptors in erythrocytes have been found 
in patients with Beckwith-Wiedemann-Syndrome (exophthalmus, 
macroglossia and gigantism), suggesting increased end-or-
gan sensitivity to insulin resulting in overgrowth (Herz-
berg et al., 1979). Fetal overgrowth has bee~ experimental 
5 
ly generated in the fetal rat and monkey by direct injec-
tion or chronic infusion of insulin (McKormick et al., 
1979; Susa et al., 1979). In contrast, fetal undergrowth 
has been observed in infants with hypo-insulinemia or de-
creased sensitivity to insulin, as found in pancreatic agen-
esis or end-organ receptor defects (leprochaunism) (O'Er-
cole et al., 1977; Taylor et al., 1982; Kaplowitz et al., 
1982a). Although anencephalic infants are of normal length 
at birth, neither GH nor any pituitary tissue is detectable 
after careful postmortem examination (Cheek et al., 1977). 
From experiments monitoring the growth of the decapitated 
fetal rat, it has been concluded that the pituitary gland 
only has a minor influence on fetal somatic growth (Liggins, 
1974). Of specific interest, however, is the important ob-
servation of the "experiment of nature" in anencephalies by 
de Gasparo and Hoet (1970): in anencephalies born to healthy 
mothers, the percentage of endocrine tissue in the pancreas, 
the number of beta-cells and the insulin cord values have 
been found to be the same as in normal infants. In anenceph-
alies born to gestational Diabetic mothers, pancreatic 
endocrine tissue, the number of beta-cells and cord insulin 
levels remained unchanged in the absence of a hypothalamus-
hypophysis. Yet, in the presence of an intact hypothalamus-
hypophysis in the above situation, the pancreatic endocrine 
tissue was enlarged, the cord insulin concentration high and 
birth weight and length were increased to the same degree 
as in the 11 normal" child of a diabetic mother. This "experi-
ment of nature" suggests that the hypothalamic-pituitary 
axis acts through the endocrine pancreas to modify fetal 
growth. 
Before discussing at length the intriguing recent devel-
opment in research concerning the function in utero of so-
matomedin (SM) or insulin-like qrowth factor (IGF), i.e., 
peptide hormones postnatally mediating the growth promoting 
6 
actions of pituitary growth hormone, it seems fitting to 
first remark on some aspects of: 
- the early development of the hypothalamo-pituitary system; 
- the ontogeny of fetal GH; 
- the somatomedin concept. 
1.2. The development of the fetal hypothalamo-pituitary system 
In contrast to previous understanding that the human pi-
tuitary gland develops from two distinct areas of the 
brain- ectodermal and neuroectodermal in origin-, recent 
evidence from anatomical studies in avian embryos suggests 
the Rathke's pouch to arise from the most caudal extension 
of the ventral neural ridge. Consequently, both the hypo-
thalamus and the adenohypophysis can be regarded as embry-
onic derivates from a common neuroectodermal anlage (Taker 
et al., 1975). In vertebrates, most cells producing hormonal 
peptides belong to a family of cells known as the APUD se-
ries (amine content and/or precursor uptake and decarboxy-
lation). These cells are all thought to be of neuroectoder-
mal origin. This means that the hypothalamo-pituitary 
axis is not to be considered an interaction between clas-
sical neurons and endocrine cells, but a communication be-
tween two units of a complex peptidergic nervous system 
(Pearse et al., 19 79). 
The hypothalamus is the first of the forebrain regions 
to differentiate. It is recognizable at 22 days of fetal 
age. Between 6-12 weeks of gestation, a rapid differenti-
ation occurs of various nuclei (supraoptic, paraventric-
ular, dorsomedial, arcuate and mamillary). Neurotrans-
mitters, such as dopamine, serotinin, norepinephrine 
and hypothalamic hormones (releasing factors), become de-
tectable (Goodyer, 1981). The adenohypophysis develops 
from an outpocketing of the roof of the pharyngeal region 
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closely attached to the floor of the diencephalon (Rathke's 
pouch). At about 5 weeks of fetal age, a vascular network 
appears in the connective tissue immediately surrounding 
Rathke's pouch. Epithelial cells divide rapidly, forming 
small follicular structures. Neuroblasts begin to differen-
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Fig. I.l. 
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COELIAC DISEASE 
Schematic diagram of the hypothalamo-hypophyseal unit, its hypo-
thetical pathways and mechanisms involved in the secretion of 
growth hormone_ (From: Vanderschuren-Lodewijckx, 1981; reprinted 
with permission of author and publisher_) 
tiate in the overlying hypothalamus and a primitive neuro-
hypophysis is formed. At 3 months of gestation, an anterior, 
intermediate and posterior hypophysis can be recognized. All 
pituitary peptides are demonstrable in specific granulated 
cells through immunohistochemical techniques (Goodyer, 1981) 
In the meantime, the vascular supply to the hypothalamic 
and pituitary region is developing into a complex portal 
system. Thus, the hypothalamus and pituitary are likely to 
interact at a very early stage of gestation. Maternal pi-
tuitary hormones do not cross the placenta, so the fetus is 
dependent on the secretions of its own pituitary, supple-
mented with various analogous hormones produced by the pla-
centa. However, pharmacological doses of TRH given to par-
turient women have been shown to increase TSH and GH in 
cord blood (Roti et al., 1981, 1982). 
i:;'1t~,E'!IIA MEDIANA 
TUBER CINEREUM 
:PORTAL VESSELS I 
SOMATOTROPHIC CElLS 
LIMBIC SYSTEM 
HYPOTHALAMUS 
8F HtE PITUITARY GLAND 
ANTERIOR LOSE 
Fig. I.2. 
Schematic diagram of the hypothalamo-hypophyseal unit and of hor-
monal interactions involved in the secretion of growth hormone (GH) , 
production of somatomedin and somatic growth. (From: Vanderschuren-
Lodewijckx, 1981; reprinted with permission of author and publisher.) 
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1.3. The ontogeny and regulation of fetal growth hormone 
In postnatal life, GH is regulated by a dual mechanism 
consisting of the hypothalamic growth hormone releasing 
factor (GRF), the existence of which has been demonstrated 
just recently (Thorner et al., 1982; Rivier et al., 1982), 
and of the inhibiting factor somatostatin (SRIF). Both pep-
tides are modulated in turn by various biogenic amine sys-
tems within the hypothalamus as well as by other peptides 
(fig. I.l.). 
There are no indications that the principles of the reg-
ulatory mechanisms during fetal life are in any way dif-
ferent from those found in later life. A schematic repre-
sentation of the complex regulation of GH is given in fig. 
I. 2 0 0 
GH can be detected in fetal plasma by 7 weeks of gesta-
tion. Its concentration rises from 65 = 7 ng/ml at 10-19 
weeks of gestation to a peak of 132 + 22 ng/ml at 20-29 
weeks, which is probably the result of a relatively autono-
mous secretion. Subsequently, these acromegalic values de-
cline. This coincides with the development of the hypothal-
amo-pituitary system, when the regulatory mechanisms, both 
stimulatory and inhibitory, become operative, as well as 
with further maturation of the central nervous system {Gluck-
man et al., 1980). At birth, the GH regulatory mechanism is 
not fully developed yet, as is shown in the following obser-
vations (Goodyer, 1981): 
- basal GH values are elevated and a diurnal rhythm fails 
to unfold till up to 3 months post-partum; 
- hyperglycemia and L-Dopa or pyridoxin administration 
result in a paradoxical GH response during the first 
week of life. 
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1.4. The somatomedin concept 
1.4.1. Sulphationfactor- somatomedin- insulin-like growth factor 
In vitro, serum from intact or GH-treated, hypophysec-
tomized rats stimulates the incorporation of radioactive 
sulphate into cartilage of hypophysectomized rats. Neither 
GH itself nor serum from untreated, hypophysectomized rats 
with or without added GH has an appreciable effect on car-
tilage sulphation in vitro. This basic observation, made by 
Salmon and Daughaday, has led to the hypothesis that GH 
does not act directly on cartilage, but elsewhere in the 
body to stimulate the formation of a secondary hormonal 
mediator acting directly on cartilage (Salmon and Daugha-
aay, 1957). This mediator was initially termed sulphation 
factor. As this factor seemed to mediate at least some of 
the anabolic effects of the somatotropic hormone (GH), it 
has been renamed somatomedin. 
In the early sixties, it became evident that the insulin-
like activity (ILA) of serum - defined as the ability of 
serum to stimulate metabolic activities in muscle and adi-
pose tissue in vitro as crystalline insulin does - only 
partly consists of pancreatic insulin. The ILA of human se-
rum stays present despite an excess of insulin antibodies. 
This nonneutralizable or nonsuppressible ILA (NSILA) consti-
tutes the bulk (-'==' 90%) of ILA in fasting human serum (Jakob 
et al., 1968). Subsequently, it has been observed that par-
tially purified SH exhibits insulin-like activity in vari-
ous bioassays and that SM and !LA are co-purified in such 
a way that the two bioactivities maintain a fairly constant 
ratio. These and other observations noint to a close simi-
larity, if not identity of SM and NSILA in human serum. 
This identity has been validated by Rinderknecht and Hum-
bel who discovered the aminoacid sequence of two peptides, 
for which they proposed the generic names insuJ in-like 
ll 
growth factor (IGF) I and II. IGF-I and IGF-II have a 62% 
aminoacid sequence identity and are 38-48% homologous with 
the A and B domains of human pro-insulin (Rinderknecht and 
Humbel, 1976, 1978a, 1978b). Several types of SM peptides 
have been isolated from human plasma, termed differently 
depending on the assay used x1), namely SM-A, SM-C, IGF-I, 
IGF-II and ILAS, all having a molecular weight of 7,000-
9,500 and an isoelectric point range of 4.4-9.8 (Van den 
Brande and Hoogerbrugge, 1980; Guyda et al., 1981b) x2) 
As more structural information is being acquired, several 
of the peptides may prove to be identical (Klapper et al., 
1983) (table I.l.). A summary of in vitro and in vivo ac-
tions of SM is presented in tables I. 2. and I. 3. (after 
Phillips and Vasiloupoulou, 1980). SM levels in plasma are 
in accordance with the original definition of GH dependence, 
low in patients with GH deficiency and high in ac:r0megalics. 
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Bioassays refer to the biologic activity of a test sample in com-
parison with a "standard" preparation {hence the term somatomedin 
activity (SMA)). Various in vitro bioassays have been developed, 
based on the different tissue effects of SM (table I.2.). The por-
cine cartilage bioassay, by which the incorporation of radiolabeled 
sulphate into cartilage is measured, is most frequently employed 
{Van den Brande and Du Caju, l974al. 
In radioreceptorassays (RRA), competitive protein binding assays 
(CPBA) and radioimmunoassays (RIA), displacement of radiolabeled 
somatome din is measured from cell membrane preparations, crude car-
rier protein fractions or antibodies respectively. The sensitivity 
and specificity of these tests vary considerably (for a review the 
reader is referred to Phillips and Vasiloupoulou, 1980, and Guyda 
et al., 198lb). 
With the exception of NSILP, a large molecular weight NSILA which 
cannot be converted into small fractions under actdic cor.C.i tions and 
does not cross-react in a CTlT3.:l.. for NSILA (Poffenbarger et al., 1979; 
Zap£ et al., 1978). 
Exceptions to this rule have been observed. In addition, 
there are indications that the modulation of insulin secre-
tion and the nutritional status play a major role in the 
regulation of the secretion of SM peptides (Phillips et al., 
1976, 1979a, 1979b; Price et al., 1979) (fig. I.2.). In 1978, 
Van Buul-Offers and Van den Brande showed that a somatornedin 
preparation, devoid of anabolic hormones, produces body 
growth in the congenitally GH-deficient Snell mouse to the 
same degree as growth hormone does (Van Buul-Offers et al., 
1979). These findings, recently confirmed by Schoenle using 
pure IGF-I and IGF-II preparations (Schoenle et al. ,· 1982a'b), 
strongly indicate the original hypothesis of Salmon and Dau-
ghaday to be correct. 
1.4.2. Somatomedin binding proteins 
There is ample evidence that SM circulates in plasma, 
mainly bound to macromolecular carrier or binding proteins 
(a.o. Zap£ et al., 1975i Hintz and Liu, 1977; Furlanetto, 
1980). When human plasma or serum is chromatographed on 
Sephadex at neutral pH, SM migrates as a large molecule; 
at acid pH, however, as a small molecule. At least two dif-
ferent binding proteins with high affinity and specificity 
for SM exist. The major one (150-200,000 MW) consists of 
two protein subunits, one of which is acid-stable and con-
tains the structural determinants necessary for binding 
SM, while the other is acid-labile (Furlanetto, 1980). The 
acid-stable subunit appears to be under GH control (a.o. 
Zap£ et al. 1 1980 i Copeland et al. 1 1980; White et al., 
1981; Schalch et al., 1982). Moreover, plasma contains 
an unsaturated, acid-stable form of an SM binding protein 
with a molecular weight of 35-40,000. Levels of this unsat-
urated SM binding protein are elevated in serum of pa-
tients with growth hormone deficiency and decline during 
GH treatment (Hintz et al. 1 1981; Borsi et al., 1982). 
Preliminary evidence has been presented, suggesting that 
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Table I. l. 
Somatomedin peptides prepared from human plasma (after Guyda, 
19 81) • 
SM MW p I sulphation growth bioassay used 
peptide effects for isolation 
IGF-I 7649 8.2-8.5 + + "c glue. uptake 
into rat adipo-
cytes 
SM-C 76 49 8.2-8.5 + 35so and 3H-
thymidine uptake 
into rat cart. 
IGF-II 7471 7.0-7.4 + J4c glue. uptake 
into rat adipo-
cytes 
SM-A 7000 7.1-7.5 + + 35so4 uptake lnto embr. 
chick cart. 
ILAS 9400 6.4-6.7 + J4c glue. uptake 
into rat adipo-
cytes 
NSILP 88.000 5.9-6. 5 l4c glue. uptake. 
into rat adipo-
cytEO!S 
Table I.2. 
Tissue effects of somatomedins (after Phillips et al., 1980) 
Cartilage-stimulating activity 
- amino-acid transport 
- synthesis of RNA 
- synthesis of DNA 
- synthesis of protein 
- formation of proteoglycan 
- synthesis of collagen 
Insulin-like activity 
Muscle 
- amino-acid transport 
- sugar transport 
- formation of glycogen 
- synthesis of protein 
~ 
- sugar transport 
- glucose oxidation to carbon dioxide 
- glucose incorporation into lipid 
inhibition of lipolysis 
Mitogenic activity 
- replication in cell cultures 
Table I.3. 
Demonstrated effects of SM in vivo (after Phillips et al., 1980) 
Insulin-like activity 
Muscle 
- sugar transport 
- glucose uptake into glycogen 
- protein synthesis 
Fat 
- glucose incorporation into lipid 
- decreased lipolysis 
Whole animal 
- increased glucose turnover 
hypoglycemia 
growth promoting activity 
alkaline treatment of serum Cohn fraction IV results in a 
breakdown of the large molecular weight binding proteins 
into smaller complexes of approximately 40,000 and 30,000 
MW (~1orris and Schalch, 19 82). The binding nroteins are 
probably generated in the liver. Binoux recently provided 
evidence of the existence of two binding proteins in cul-
ture media of adult livers. Both have a molecular weiqht 
of approximately 40,000,but a different affinity for IGF-I 
and IGF-II (Binoux et al., 1982). 
1.4.3. Somatomedin inhibitors 
Under catabolic conditions, such as acute or chronic 
starvation and diabetic ketoacidosis, low values of SM are 
found in humans as well as in rats (Grant et al., 1973; Van 
den Brande and Du Caju, 1973; Phillips et al., 1976; Hintz 
et al., 1978; Clemmons et al., 198lb; Merimee et al., 1982a, 
Isley et al., 1983). The relationship between SM and other 
hormones is unclear. Starvation results in elevated GH 
levels, an inability of administered GH to raise serum SM 
levels and a peripheral resistance to the action of GH 
(Phillips et al., 1976; Hintz et al., 1978). No significant 
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correlation has been found between SM-C and decreased insu-
lin values during fastinq and refeeding of adults (Isley 
et al., 1983). During starvation, glucose utilization by 
the periphery is reduced and fatty acids and aminoacids are 
primarily used for fuel expenditure rather than for de novo 
protein synthesis. Inhibition of peripheral glucose uptake 
is a typical property of GH. Low SM values, therefore, seem 
to permit the utilization of mobilized substrate for fuel 
homeostasis rather than for cell growth and proliferation. 
Thus, Merimee postulated that changes in insulin concentra-
tions modulate the mobilization of substrate during fasting, 
whereas changes :i.n GH and SM modulate the substrate pattern 
of usaqe (Merimee et al., lq82a). What causes the decrease 
of SN values during starvation is not exactly understood. 
Serum of starved,ketoacidotic 9atients displays inhibitory 
activity of SM action in various bioassays (Van den Brande 
et al., 1973; Salmon, 1975; Phillips et al., 1979a, 1979b). 
This inhibitory activity is not due to glucagon, fatty 
acids or ketone bodies. Glucocorticoids are thought to 
exert no direct inhibitory activity, although recent evi-
dence points out that corticosterone may inhibit the so 4-
incorporation into hypophysectomized rat cartilage (Bombay 
et al., 1983). The inhibitor, present in starved rat serum, 
is probably a nonpituitary-dependent, acid-stable, pH-de-
pendent and heat-labile protein with a molecular weight of 
27,000-40,000 (Salmon et al., 1983). This protein and the 
inhibitor, present in serum of diabetic rats, may be iden-
tical. The inhibition of SM activity cannot be ex9lained 
on the basis of simple binding or inactivation of SM. 
On the other hand, the presence of carrier proteins has 
been shown to alter the bioavailability of SM. The oassage 
of the SM-carrier-protein complex through the walls of blood 
capillaries is restricted (Meuli et al., 1978). The metabol-
ic activity of SM, when bound to binding proteins and meas-
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ured by various bioassays, is reduced (Chochinov et al., 
1977; Zap£ et al., 1979; Drop et al., 1979; Knauer et al., 
1980). Thusfar, the only documented function of SM carrier 
proteins is to increase the circulating half life of in-
jected SM activity from a few minutes to several hours 
(Cohen and Nissley, 1976; Kaufmann et al., 1977). As out-
lined above, it is also possible that the SM binding pro-
teins protect certain tissues from the unopposed biologi-
cal activity of SM (!1euli et al., 1978; Zapf et al., 1979). 
Knauer and Cunningham (1982) established a completely 
different function of SM carrier proteins: they reported 
on a carrier protein {CP) for epidermal growth factor (EGF). 
EGF is an SM-like peptide, originally extracted from male 
mouse submaxillary glands. CP possesses arginine endopepti-
dase activity and proteolytically processes pro-EGF (9,000 
MW) to EGF (6,045 MW). In vivO and vitro, CP forms high mo-
lecular weight complexes with EGF (74,000 MW), composed of 
two EGF and two CP molecules. In addition, purified CP, free 
of contaminating EGF activity, has been shov.m to potentiate 
the proliferative response of human foreskin fibroblasts 
to EGF. Labeled CP binds to a single form of cell secreted 
protein, termed "carrier protein nexin" (CPN) . This CP-CPN 
complex is bound to the cell surface via a receptor for the 
CPN portion of the complex and subsequently internalized. 
In conclusion: SM binding proteins may be important de-
terminants of biological effects of circulating SM. 
1.5. Somatomedin and fetal growth 
Various elements indicate that somatornedin is involved 
in the humoral regulation of fetal growth. 
- First of all, there are the "experiments of nature 11 • A 
decreased birth length is found in patients with Laron 
type dwarfism and in the African pygmy. Laron type dwarf-
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ism is characterized by extremely short stature due to a 
defect in the GH receptors, which results in low serum SM 
values and high GH levels (a.o. Laron et al., 1971; Van 
den Brande et al., 1974). In the African pygmy, IGF-I de-
ficiency has been demonstrated (Merimee et al., 1981). An 
increased birth length has been found in one infant with 
Beckwith-Wiedemann-Syndrome, with markedly elevated SM 
activity in cord blood (Ashton et al., 1978). 
- The fi:r.st stage in the action of peptide hormones, such 
as somatomedin, is their binding to specific receptor 
sites on the plasma membrane of their target cells. Spe-
cific receptors for radiolabeled SM have been detected 
in various human fetal tissues (Sara et al., 1983). 
- SM concentrations are detectable in fetal serum. The 
pattern of serum SM-C concentrations in fetal sheep 
during gestation parallels the increase in fetal weight 
and crown-rump length (Handwerger, 1983). 
- Levels of SM activity in cord blood correlate signifi-
cantly with fetal and early postnatal growth (Brinsmead 
and Liggins, 1979a; Sara and Hall, 1980). 
- FurthermoreJ fetal cells endogeneously produce sontatorne-
dins (D'Ercole et al., 1980b; Hill and Milner, 1981). 
- Lastly, SM has a direct growth promoting effect on fetal 
cells in vitro (Sara et al., 1981; Hill et al., 1983; 
Kap1owi tz et al. , 19 82b). 
1.6. SM levels in fetal body fluids 
Ethical standards obviously place restrictions on the 
investigation of fetal and perinatal endocrine physiology 
in humans. Measurements of SM activity, therefore, have been 
performed partly in amniotic fluid, but mostly in cord se-
rum, in the expectation that they should reflect fetal lev·~ 
els rather than changes specific to parturition. Low SM bio-
activity was found in amniotic fluid (Anderson et al., 1974; 
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Bala et al. 1 1976, 1978; Hill and Hilner, 1981). It was 
higher at term than in early pregnancy. SM radioreceptor-
assay activity was high in preterm amniotic fluid and low 
in term samples (Moberg et al., 1976). However, both Chochi-
nov and Drop, using a radioreceptorassay for SM as well, 
independently have established the presence of a binding 
protein for SM. No small molecular weight S~1-like peptides 
have been demonstrated (Chochinov et al., 1977; Drop et al., 
1979). The levels of this binding protein in amniotic fluid 
were highest at mid gestation; their subsequent decrease 
correlated with fetal renal maturation, suggesting a fetal 
origin of the binding protein (Chochinov et al., 1976). 
It has been puzzling vrhy SM activity in cord hlood, 
whether measured by (postnatal) cartilage assay, radiore-
ceptorassay or radioimmunoassay, is low in comparison with 
serum of adults, while simultaneously GH values are elevat-
ed and body growth and skeletal maturation rapidly increase 
during the last trimester (Sara et al., 1980; Goodyer et al., 
1981; Hill and Milner, 1981). Hill and Milner (1981) inves-
tigated the following three explanations: 
a. Hormonal influence other than that of SM on fetal car-
!ilage 
Physiological or pharmacological doses of purified hor-
mones, such as insulin, GH, PRL and ~1SH, did not promote 
growth of fetal human or rabbit cartilaae. Fetal rat 
cartilage was stimulated to an equal extent by plasma 
from hypophysectomized adult rats as v.Tell as from in-
tact rats. The stimulatory activity of the hypox-rat 
plasma was considerably reduced in cartilage obtained 
4 days postnatally. 
In conclusion: fetal rat cartilage responded to a 
non-growth hormone dependent factor in hypox-rat plasma 
to which postnatal cartilage was refractory. 
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b. Detection of the predominant forms of fetal sa in assays 
for postnatal SM 
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SH activity was measured in fetal rabbit serum by rabbit 
cartilage bioassay with cartilage obtained from fetal 
and adult rabbits. In the postnatal cartilage assay, the 
activity was less than half of that found in the fetal 
rabbiL cartilage assay. Fetal cartilage, therefore, rec-
ognized stimulatory factors in fetal plasma which were 
not detected in the postnatal cartilage. Several recent 
observations made in rats have suggested a possible 
role for IGF-II in fetal growth. IGF-II levels were 20-
100fold higher in fetal rat serum than in maternal se-
rum1 declining within days after birth (Moses et al., 
1980). IGF-I levels unfolded the reciprocal developmen-
tal pattern: low·in the early neonate, rising to adult 
levels by approximately 4 weeks of age (Daughaday et al., 
1982b). Fibroblast cultures from rats of 2 to 50 days 
of age mimicked the developmental switch from IGF-II to 
IGF-I production observed in serum (Adams et al., L983). 
Sara measured SM activity in human serum by radiore-
ceptorassay, utilizing human fetal brain plasma membrane 
as matrix (Sara et al., 1981). Levels in fetal serum 
were found to be increased, not only compared with adult 
values, but also with SM values measured by radioimmuno-
assay. On the basis of this discrepancy between SM val-
ues measured in fetal serum by RRA and RIA, it was postu-
lated that in the human fetus an embryonic form of SM 
exists. At the end of the first half of gestation, this 
embryonic SM was present in high concentrations. During 
the second half of gestation, the values gradually fell 
as adult forms of SM began being produced. In this study, 
however, native serum was tested and fetal serum was not 
subjected to another radioreceptorassay. Consequently, 
interference of binding proteins v.ras not taken into ac-
count. D'Ercole was fi:cst to suggest the presence of 
binding proteins in fetal serum (D'Ercole et al., 1980d). 
He reported on the elution profile of plasma of preterm 
newborns (of 27 weeks of gestation or less). The immuno-
reactive SM-C eluted predominantly at an apparent molec-
ular weight of 40,000. Infants of 30 weeks of gestation 
or more showed an elution profile similar to that of 
postnatal sera (elution at a molecular weight of approxi-
mately 150,000). One anencephalic infant of 43 weeks of 
gestation exhibited only a 40,000 MW SM, suggesting GH 
or other pituitary hormone dependence (D'Ercole, 1980). 
NSA (multiplication stimulating activity) is an insu-
lin-like growth factor, isolated and purified from serum-
free medium conditioned by a rat liver cell line. It is 
now considered to be the rat counterpart for IGF-II: 
finding high levels, Moses tested Sephadex-G75 chromate-
graphed fetal rat serum in three different assays: radio-
immunoassay, rat liver membrane radioreceptorassay and 
competitive binding protein assay (Moses et al., 1980). 
In conclusion: In respect of a human form of embryon-
ic SM, the data at present are inconclusive. 
c. Cartilage sensitivity in the fetus 
The sensitivity of rib cartilage in vitro to a fixed SM 
stimulus was found to be higher in late fetal life than 
postnatally (Hill and Milner, 1981). Human fetal circu-
lating mononuclear cells had twice as many receptors for 
SM as adult cells (Rosenfeld et al., 1979). 
In conclusion: A rapid fetal growth rate may partial-
ly be the result of an increased tissue receptivity to 
SM. 
1.7. The origin of somatomedin in the fetus 
SM in the fetus does not 
since it does not cross the 
appear to be of maternal origin, 
a placenta (D'Ercole et al., 1980 ) 
In adults, the liver has been implicated as the major site 
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of production. So have been kidney and muscle (McConaghey 
and Dehnel, 1972; Hall and Bozovic, 1969). Not only cul-
tured human fibroblasts are recently shown to synthesize SM 
{Atkinson et al., 1980; Clenunons et al., 1981), but several 
fetal tissues release immunoreactive SM in culture as well 
(D'Ercole, 198Gb). Therefore, D'Ercole proposed the hypothe-
sis that the primary actions of somatomedin take place at 
its sites of origin (D'Ercole et al., 198Gb). 
1.8. The hormonal control of somatomedin in the fetus 
At present, the SM regulatory system during fetal growth 
is largely unknown. Following decapitation or hypophysec-
tomy in utero, body growth and skeletal maturation proceeded 
normally. In several animal studies, somatomedin activity 
proved not to be reduced despite the absence of immunoassay-
able GH (Hill and Milner, 1981; Brinsmead and Liggins, 1979; 
Daughaday et al., 1979). Factors other than GH have been in-
vestigated. Insulin administration in utero increased SM 
activity in the fetal circulation (Hill and Milner, 1981). 
There is limited information about the influence of nu-
trition on SM in fetal animals. SM bioassay activity was 
decreased in serum of fetal guinea pigs with intrauterine 
growth 
the SM 
retardation due to uterine artery ligation. However, 
concentration measured by 
er than in sorum of normal fetal 
radioimmunoassay was high-
guinea pigs (Lafeber, 1981). 
Recent data, acquired in young weaned rats, have suggested 
that caloric intake and especially protein content of the 
diet influence serum SM concentrations (Prewitt et al., 
1982). Similar results were obtained in fasting and refeed-
_ing studies in human adults (Clemmons et al., 1981; Isley 
et al., 1983). 
Underwood proposed the hypothesis that placental lacto-
gen (PL) is the primary regulator of SM in the fetus (Un-
derwood et al., 1979). Ovine placental lactogen was found 
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to be equipotent with ovine GH in raising SM levels in 
serum of hypophysectomized rats (Hurley et al., 1977) hPL, 
also known as human chorionic somatomarnrnotropin (hCS) and 
hGH show an 85% homology in terms of aminoacid sequence 
(Bewley and Li, 1974). hCS is secreted by the syncytio-
trophoblast into the maternal circulation, and only minute 
fractions end up in the fetal circulation (Baumann, 1979) 
Therefore, it seems unlikely that hCS regulates fetal SN 
Table I.4. 
Major functions of the human placenta (after Deal, 1981) 
I. Transport (by ultrafiltration, gradient diffusion, carrier-
mediated active transport, phagocytosis, pinocy-
tosis) 
Substrates sugars 
- amino acids 
- fatty acids 
- Other nutrients 
vitamins 
- trace metals 
- minerals 
- electrolytes 
- H20 
II. Hormone synthesis 
- Steroid hormones 
- progesterone 
-estrogens (E 1 , E2 , E3 l 
- Protein hormones 
III. Respiration 
- placental lactogen 
- chorionic gonadotropin 
- chorionic thyrotropin 
- chorionic follicle stimulating hormone 
chorionic corticotropin 
- ACTH and related molecules (aMSH, ~LPH, 
~endorphin) 
- o 2;co2 exchange 
IV. "Barrier" to host rejection of fetus 
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secretion directly. Very recently, however, a direct in 
vitro stimulatory effect of PL on IGF-II synthesis in fe-
tal fibroblasts has been demonstrated (Adams et al., 1983). 
In addition, hCS, as a GH-like hormone, may very well in-
fluence the maternal fuel metabolism, a major factor in fe-
tal growth (Kaplan and Grumbach, 1979). 
In this respect, the crucial role of the placenta should 
be mentioned. A summary of its multiple functions is given 
in table I.4. (adapted from Deal, 1981). Placental tissue 
is noted for its rich source of receptors for insulin and 
various SM peptides. Specific binding has been found of la-
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Schematic diagram of hormonal determinants of fetal growth. 
Placental lactogen {PL) is a primary regulator of somatomedin in 
the fetus. In addition, growth hormone (GH), prolactin (PRL), the 
nutritional status and insulin almost certainly influence fetal so-
matomedin production (Underwood et al., 1979). (From: Deal, 1980. 
Thesis, McGill University, Montreal; reprinted with permission of 
the author.) 
beled SM to cell membranes, prepared from cell cultures of 
human placentae obtained at early gestation and at term 
(Deal, 1982). These receptors are primarily localized on 
the microvilli of the syncytiotrophoblast and, therefore, 
would be responsive merely to maternal insulin (Nelson et 
al., 1978; Whitsett et al., 1979). Yet, in insulin-treated 
fetal rhesus monkeys, the placenta is shown to be increased 
in size despite normal maternal insulin levels (Susa et al., 
19 79). 
In conclusion: Maternal and fetal SM may be potential 
regulators of placental metabolism. 
1.9. Concluding remarks 
The presence of growth promoting factors in the fetus 
has been recognized since the beginning of this century. 
Up to the present, embryonic extracts and fetal calf serum 
are being used to stimulate growth of cells in culture. The 
nature of the embryonic ingredients remains obscure (Sara 
et al., 1980). Understandably, somatomedin has been impli-
cated as the actual fetal growth factor. As was pointed 
out, however, many questions in regard to its identity, 
origin, mode of action and regulation still go unresolved. 
A hypothetical and schematic representation of hormonal de-
terminants of fetal growth is given in fig. I. 3. (after 
Deal, 1981). Binding proteins may play a physiological key 
role in determining the bioavailability of SM acting pri-
marily at its sites of origin (D 1 Ercole, 1980). 
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CHAPTER II 
PARTIAL PURIFICATION AND CHARACTERIZATION OF A BINDING 
PROTEIN FOR INSULIN-LIKE ACTIVITY (!LAs) IN HUMAN AMNIOTIC 
FLUID: A POSSIBLE INHIBITOR OF INSULIN-LIKE ACTIVITY 
Stenvert L.S. Drop, Guy Valiquette, Harvey J. Guyda, 
Maite T. Corvo/ and Barry I. Posner. 
Departments of Paediatrics and Medicine, McGill University, 
Montreal, Canada, and INSERM U. 30, H6pital des Enfants-Malades, Paris. 
11.1. Introduction 
The most rapid growth in human cell number and cell 
size occurs during the intra-uterine and immediate post-
natal periods of life (Cheek, 1968; Winick, 1971; Winick 
& Noble, 1965). The factors regulating intra-uterine 
growth are poorly understood. Growth hormone (GH) from the 
maternal or fetal pituitary may not be rate limiting (Bliz-
zard & Alberts 1956; Chez et al., 1970; Jost, 1947; Laron 
& Pertzelan, 1969; Rimoin et al., 1966; Van Assche et al., 
1969; Wells, 1947), although definitive human fetal studies 
of pituitary secretion of GH and of prolactin (PRL) in vivo 
have not been performed. 
The importance of the effect of other factors, including 
insulin and somatome din (SM) (Chochinov & Daughaday, 19 76; 
Daughaday et al., 1972; VanWyk et al., 1974; VanWyk & 
Underwood, 1975), on somatic and skeletal growth in the 
fetus remains speculative. However, the significantly re-
tarded birth length observed in infants with Laron dwarfism 
(Laron & Pertzelan, 1969; Laron et al., 1968) suggests that 
somatomedin may affect fetal growth. The hormones or factors 
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which promote synthesis and secretion of somatomedin in 
the fetus are unknown. Somatornedin bioactivity is low in 
amniotic fluid (Bala et al., 1978). Somatomedin bioactiv-
ity (Svan et al., 1977; Tato et al., 1975) and somatomedin 
reactivity, determined by radioreceptorassay (RRA) or ra-
dioimmunoassay (RIA) , are also decreased in cord blood 
(Heinrich et al., 1978). 
Chochinov (1977) has described a protein in midterm hu-
man amniotic fluid that reacted in the somatomedin-C RRA 
by binding labeled SM-C and that was capable of inhibiting 
the stimulation of thymidine uptake induced by human serum 
and by rat SM in human fibroblast cultures (Chochinov et 
al., 1977). The significance of this amniotic fluid binding 
protein in relation to fetal growth is uncertain. 
In this repor~we confirm and extend the observations 
by Chochinov et al. (1977). Our studies have been carried 
out with an insulin-like somatomedin peptide (ILAs) that 
we have partially purified in our own laboratory (Posner 
et al., 1977, 1978). Using a radioreceptorassay for this 
peptide!we have been able to characterize and partially 
purify a protein from human amniotic fluid (AFBP) that 
specifically binds ILAs and inhibits its bioactivity in 
vitro. 
11.2. Materials and methods 
l!.2.1. Radioreceptorassay (RRA) for insulin (INS) and insulin-like activity (!LAs) 
The RRA procedure was identical to the methods employed 
for INS and ILAs, as described previously (Posner et al., 
1977, 1978). AFBP is reactive in the ILAs-RRA, but because 
of nonparallel displacement quantitative results( report-
ed as ng equivalents of porcine insulin (1 ng equivalent 
equals 25 ~U insulin)) should be taken as an approximation 
only. 
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In order to study the binding of AFBP to the placental 
receptor, the ILAs-RRA was modified as follows: in each 
assay tube,0.1 ml of the placental membrane suspension 
and 0.1 ml of ILAs standard of AFBP were combined in a 
total volume of 0.5 ml of assay buffer (25 mM Tris, 10 mM 
MgC1 2 , 0.1% BSA (Sigma), pH 7.4) and pre-incub~ted at 4°C 
for 2 hours with continuous agitation. The incubation was 
stopped with the addition of 3 ml of ice-cold assay buffer. 
The tubes were then centrifuged at 750 x g for 30 minutes, 
the supernatant was decanted, and the membrane pellet was 
rinsed once with 3 ml of ice-cold buffer. The membrane 
pellet was then incubated with 125 r-ILAs (20,000 cpm) at 
4°C for 2 hours with continuous agitation, as in the usual 
assay conditions. Following the addition of 3 ml of ice-
cOld assay buffer, membrane bound radioactivity was sep-
arated by centrifugation and counted in a gamma spectro-
meter (Packard Model 5120, efficiency of 40%). 
JJ.2.2. Purification of AFBP 
JJ.2.2.a. Amniotic fluid (AF) 
Amniotic fluid was collected per vaginam at the time of 
rupture of the membranes from normal pregnant women at 
term (AF ). Early gestational AF (AF t ) was ob-term pre erm 
tained for various diagnostic purposes by amniocentesis at 
a gestational age of 14-20 weeks. Any sample showing more 
than minimal blood contamination was discarded. The samples 
were pooled, frozen and stored at -20°C until processed. 
Upon thawing, the pooled fluid was cleared of particulate 
matter by filtration through cheese cloth, then through 
moarse filter paper and finally lyophilized and stored at 
4 °c unti 1 used. 
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JJ.2.2.b. Acid-ethanol extraction 
Lyophilized pooled AF powder was extracted with cold 
acid-ethanol (75% ethanol (v/v) - 0.19 M HCl, pre-cooled 
to 4°C). Lyophilized AF powder was homogenized in cold 
acid-ethanol (0.1 g/ml) in a Waring blender for 4 minutes 
and stirred at room temperature for 30 minutes. The sus-
pension was then centrifuged at 30,000 x g for 30 minutes. 
The supernatant was dialyzed (Spectropor-3) against dis-
tilled H2o for 48 hours and then against 0.01 !-1 HCl for 
24 hours. The dialysate was frozen and lyophilized. 
II.2.2.c. Column chromatography 
Gel filtration of lyophilized dialysate was performed 
on 5 x 100 em columns of Sephadex G-150 {Pharmacia Fine 
Chemicals Inc., Uppsala, Sweden) at 4°C. The following 
buffer systems were used for purification: 
0.01 M NH 4Hco 3, pH 7.4, and 0.01 M HCl, 0.1% bovine serum 
albumin (BSA) (Sigma), pH rv-2. The elution volume of the 
amniotic fluid binding protein (AFBP) was determined by 
radioreceptorassay for ILAs (vide supra) on the eluted 
fractions. The void volume (V0 ) and the total volume (Vt) 
of the column were determined with 125r-labeled bovine 
thyroglobulin and 125 r respectively. Column fractions 
with the highest reactivity in the ILAs-RRA (Kd 0.4 to 0.5} 
were pooled and lyophilized. 
//.2.2.d. Preparative isoelectric focusing 
Preparative isoelectric focusing of AFB~ obtained fol-
lowing Sephadex chromatography, was carried out in a sucrose 
gradient (5-50%) stabilized column (LKB 440 ml) at 4°C. A 
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2% solution of Ampholine (pH 3-6) was employed. The anode 
solution consisted of 0.25 M H2so4 in 80% (v/v) sucrose. 
The cathode solution was 0.25 M NaOH in water. After 72 
hours, the column was emptied from below with continuous 
monitoring of absorbance at 280 nm. Eluate fractions were 
grouped and pooled according to pH and extensively dialyzed 
first against distilled water for 48 hours, then against 
0.01 M HCl for 24 hours. Fractions with the highest specif-
ic activity (pH range 4.7 to 4.9) were lyophilized, re-
dissolved in 0.01 M HCl and re-chromatographed on Sephadex 
G-150 in the same buffer (column size 2.2 x 40 em). 
JJ.2.2.e. Iodination 
AFBP was iodinated by a modification of the chloramine-
T method. Partially purified material (5-10 ~g protein) 
was added to 0.5 M phosphate buffer, pH 7.4 (10 ~1), 1.0 
mCi Na- 125 r (10-20 vll and 40 vg of chloramine-T (25 vl). 
The reaction was terminated after 30-45 seconds with the 
addition of 250 ~g of 
100 vg of KI 
sodium metabisulphite (100 ~1), fol-
(100 ~1). This mixture was chromate-lowed by 
graphed directly on a Sephadex G-150 column (2.2 x 40 em) 
at 4°C, with 0.01 H HCl as eluting buffer. Only fractions 
eluting at a Kd of 0.4-0.5 were used for further studies. 
JJ.2.3. Analytical procedures 
!!.2.3. I. Electrophoresis 
Analytical polyacrylamide (disc-)gel electrophoresis 
(PAGE) was carried out with a 10% acrylamide separative 
gel, a 3% acrylamide concentrating gel and a continuous 
buffer system of Tris-glycine-HCl, pH 8.3. SDS-polyacryl-
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amide disc-gel electrophoresis was performed as described 
by Laemli (1970). 
J/.2.3.2. Jsoe/ectric focusing 
Analytical isoelectric focusing was performed at 4°C in 
7.5% polyacrylamide, 5% glycerol and 7 wM riboflavin-5'-
phosphate containing 2% Amopholine (biolyte, Biorad, Cal. )1 
pH range 3-6. The cathode solution consisted of 0.02 M 
Ca(OH) 2 and 0.04 M NaOH and the anode solution was 0.06 M 
H2so4 . Electrophoresis was carried out at 200 V for 18-22 
hours. The gels were subsequently frozen on dry ice and 
sectioned into fractions with a Mickle gel slicer. Slices 
(3 mrn) were incubated with shaking for 16 hours in 0.5 ml 
dis·tilled water after which pH, ILAs-R:RA reactivity or 
radioactivity of 125 r-labeled material was determined. 
/1.2.3.3. Molecular weight estimation 
The molecular weight of AFBP was estimated by gel fil-
tration on a Sephadex G-150 column (2. 2 x 40 cm)f calibra-
ted in 0.1 M ammonium acetate, pH 7.4. As molecular weight 
standards the following proteins and peptides were chroma-
tographed: aldolase 15 8 1 0 00; ovalbumin 4 5, 0 0 Oi chymotryp-
sinogen A 25,000; ribonucluolease (RNase) 13,700; parathy-
roid hormone 9,500; calcitonin 3,400. 
Jl.2.3.4. Bioassays 
Bioactivity of AFBP alone and AFBP in combination with 
ILAs was studied in chondrocyte cultures, prepared from 
rabbit growth plate and articular chondrocytes (Corvol et 
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al., 1978), as well as in the epididymal fat pad assay as 
described previously (Posner et al., 1978). 
Protein concentration was determined by the method of 
Lowry et al. (1951) 1 with bovine serum albumin (BSA) as the 
standard, or by optical density at 280 nm. 
Statistical analysis was performed by the Student's 
t-test. 
11.3. Results 
II. 3.1. Purification 
Amniotic- fluid binding protein (AFBP) was partially pu-
rified from batches of term and preterm AF by the follow-
ing sequence of procedures: acid-ethanol extraction, gel 
filtration on Sephadex G-150 (repeated once), preparative 
isoelectric focusing and re-chromatography on Sephadex 
G-150. These procedures resulted in the isolation of sam-
ples of AFBP which had been purified from amniotic fluid 
about 825fold (table II.1.). Purification and recovery 
results should be taken as an approximation only, since 
the dilution curves in the ILAs-RRA of untreated amniotic 
fluid and AFBP at various stages of purity were not paral-
lel to the ILAs standards. These relationships are more 
I 
easily seen after logit-log transformation {fig. II.1.). 
Because of this 1 AFBP was assayed at the same protein -con-
centration at each step of purification. 
Preterrn AF contained 7-10 times more ILAs-RRA displac-
ing activity than term AF and was usually utilized as 
starting material. Lyophilized AF was extracted with acid-
ethanol (0. l g dry weight/ml), as described under Methods. 
This resulted in an approximately 7fold purification and 
removal of almost 90% of protein. Lyophilized dialysate 
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powder was dissolved in 0.01 M NH 4Hco 3 and then chromate-
graphed on Sephadex G-150. The peak RRA activity eluted 
at a Kd value of 0.4-0.5,and peak reactive fractions were 
pooled and lyophilized. This step resulted in only slight 
purification with a low recovery. Subsequently, it was 
found that higher recovery could be obtained when AFBP was 
kept at acid pH. Therefore material obtained as above was 
re-chromatographed on Sephadex G-150 (column size 3.75 x 
6 5 em) in 0 • 0 1 M HCl, pH"' . 2. 
logit 
34 
lOG (il) 
d ilutio ~ 
-I 
F PI 
-2 ' 
' 
' ' 
' 
' ' 
-3 ', 
I LA, ~AFBP 
-4 
2.5 10 25 50 100 200 ~9 equiv/ml 
_, 0 log {ng equiv/ml) 
Fig. II.l. 
Dilution curve of the !LAs standard, amniotic fluid (FPI) and 
partially purified AFBP in the ILAs-RRA. The data are shown after 
logit-log transformation. !Jnweighted linear regression analysis 
was performed upon logit-log transformed data. 
Table II. 1. 
Purification schema 
1. AF 1250 ml 
2. Acid- ethanol 
extraction 
and dialysis 
3. Sephadex G-150 
Repeated 
4. Isoelectric 
focusing 
Protein 
(Lowry) 
(mg) 
7875 
990 
2 30 
73 
8.7 
RRA Specific Recovery 
(ng equiv./ml) activity (per cent) 
(ng equiv./mg} 
1,025,000 130 10 0 
816,750 825 75 
263,120 1150 26 
232,960 3200 22 
139,776 16,000 13 
5. Sephadex G-150 0.78 83,865 107,000 6 
Purification was now about 3fold, with a recovery of 89%, 
and RRA reactive fractions eluted at Kd 0.4-0.5, similar 
to the elution profile at neutral pH. Column fractions 
with highest activity from several chromatograms were 
pooled and lyophilized. In the next step, material obtained 
as above was subjected to preparative isoelectric focusing 
(see fig. II.2. and legend for details). This procedure 
resulted in a further Sfold purification and recovery was 
estimated at 59%. The fractions with the highest specific 
activity (SA) in the pH range of 4.7-4.9 were dialyzed, lyo-
philized and re-dissolved in 0.01 M HCl and chromatographed 
on Sephadex G-150 in the same buffer (column size 2.2 x 40 
em). A protein peak at the Kd value of albumin was clearly 
separated from RRA reactive material (data not shown). This 
procedure resulted in a further 7fold purification, with a 
recovery of 60%. 
Table II.1. summarizes the results obtained throughout 
the entire sequence of procedures used for the isolation 
and partial purification of AFBP. The final recovery of 
RRA activit.y was estimated at about 6%. The apf-arent puri-
fication was 825fold. Analytical polyacrylamide disc-gel 
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electrophoresis in SDS of the final product showed one 
major protein band with an Rf of 0.44 (fig. II.3.). 
II.3.2. Molecular weight 
The molecular weight determination of AFBP was based on 
gel filtration on a standardized column of Sephadex G-150. 
In many successive runs of partially purified AFBP in neu-
tral pH buffers, the Kd values were not significantly dif-
ferent and the combined Kd value was 0.435 
2:_ SEM, n 7). The range was from 0.403 to 
+ 0.09 
0. 4 72. 
(mean 
This 
provides a molecular weight estimate of 34,500 daltons. 
pH 
6 
5.5 
5 
4.5 
4 
OD290 protein 
1 j I 
I I 
4 4.25 
Fig. II.2. 
4.5 5 
pH 
2000 
1500 
1000 
500 
Preparative isoelectric focusing. AFBP partially purified from term 
AF by acid-ethanol extraction and Sephadex G-150 chromatography 
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(2X) with SA of 335 ng equiv./mg protein was dissolved in 18 ml 
HzO {total amount of protein was 150 mg} and applied to a sucrose 
stabilized (5-50%} column (LKB 440 ml) at 4°C. Peak RRA activity 
in the eluted fractions measured after extensive dialysis was seen 
at pH 4.7-4.9. Bars represent SA in ng equiv./mg prot . 
.___. pH gradient. 
--- protein measured by 00 at 280, 
a) AF (Pre-term) 
1.0 
1.5 
0 5 
E 
, 
~ I I 
o" 
0 
b) AFBP 
0 5 i !);= 0.44 0. 2 5 
' 
Fig. II.3. 
Analytical gel electrophoresis in polyacrylamide gel (7.5%) with SDS. 
a) The main protein band of pre-term amniotic fluid (albumin) had 
an Rf of 0.44. 
b) Partially purified AFBP (100 ng equiv.) revealed only one protein 
band at Rf = 0.44. 
Il.3.3. Isoelectric point 
As indicated in fig. II.2., during preparative isoelec-
tric focusing the main RRA activity eluted at a pH of 
4.7-4.9. When AFBP, labeled with 125r as outlined under 
Methods, was subjected to isoelectric focusing in polyacryl-
amide gels, a major peak was seen at pH 4.6-4.9. A minor 
peak was found at 4.2-4.5, but it probably represents 
tailing of damaged tracer products as RRA activity was 
eluted only at pH 4.7-4.9 (not shown). 
The nature of the interaction between AFBP and ILAs was 
defined by several different kinds of studies. 
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• 
AFSP alone 
' .. .. .. 
(o. 
~'~ ~y 
~J~ 
llA; + AFBP 75 ng cqu1v. 
ILA< +AFBP 25 ng equiv. 
ILA, 
Q INS 
1·0 l-5 S 7·5 10 15 25 J5 50 75100 250 500 1000 ng equov.jml r-·--~~~~~~~~~~-r--~~~=----
0 Log lng equiv.jml) 
Results of the assay of ILAs or of a mixture of ILAs and AFBP in 
the INS-RRA (after logit-log transformation). In the mixtures, con-
centrations of ILAs in the sample can be read off the x axis and 
concentrations of AFBP (in ng equiv./ml) are indicated along the 
corresponding regression line. 
II.3.4. Interaction AFBP and I LAs 
ll.3.4.a. Radioreceptorassays 
To exclude the possibility that the RRA reactivity of 
AFBP is based in part on direct binding of AFBP to the re-
ceptor, the ILAs-RRA was modified as outlined under !'1ethods. 
Ninety ng equiv. AFBP (SA 1250 ng equiv./rng prot.), pre-
incubated with placental membranes, did not inhibit 125r-
Table II.2. 
Binding of 1251-ILAs to placental membranes after pre-incubation 
with ILAs or AFBP. 
Final concentration in ng equiv. of porcine insulin (see Materials 
and Methods) . 
Peptide 
added 
I LAs 
0.25 
1.0 
2.5 
4. 0 
AFBP 
5 
15 
30 
90 
B-N 
8 0 -N 
0.7621 
0.7380 
0.6294 
0.5638 
0.9900 
0.9903 
0.9952 
l. 050 
39 
ILAs binding to the receptor whereas 4 ng equiv. ILAs sig-
nificantly decreased specific binding (table II.2.). In 
addition, 125 r-AFBP1 incubated with receptor under usual 
assay conditions for 2, 4, 6 and 24 hours, did not reveal 
any specific binding. Finally, when a mixture of ILAs and 
AFBP was assayed in the INS-RRA, progressively higher con-
centrations of AFBP were observed to inhibit the activi-
ty of ILAs in the INS-RRA, although when assayed alone in 
the INS-RRA, AFBP was nonreactive (see fig. II.4. and leg-
ends for details). 
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AFBP 100 ng equ·lv./flosk 
250 llA 5 66 ng equiv./ flask 
200 
0 
0 
-
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"' E p < .005 
" :; 100 
~ 
u 
u 
~ 
0 100 1000 AFBP ll A 5 llA 5 + AFBP 
Insulin ~U/flask 
Fig. II.S. 
Epididymal fat pad assay. The stimulatory effect of insulin on the 
incorporation of (l4C) glucose into fatty acids is expressed as l4c 
CPM/mg tissue. Incubating AFBP (SA approximately 1000 ng equiv./ 
mg prot.) at a concentration of 100 ng equiv./flask has no stimu-
latory effect. This amount added to ILAs {66 ng equiv./flask) de-
creased the stimulatory effect of ILAs alone significantly (P<O.OOS). 
!I.3.4.b. Bioassays 
AFBP significantly inhibited the stimulatory effect of 
ILAs on 14 C-glucose incorporation into fatty acids of 
rat adipose tissue {see fig. II.S. and legend). The in-
crease of 
6 
5 
~ 
z 
Q 
• ,
f' 
0 
4 
E 
• ~ 
o• 
~ 
3 
2 
35s- sulphate incorporation into purified pro-
if-------1------ -II- -I 
' 
' 
' 
' 
' 
' 
' 
' I 
' 
' 
' 
' 
' 
' 
N=4 
' 
' 
' 
' 
' 
' 
' 
' 
· I r>t------l~~~~=~~~l;~~~~+;~~~> '""; .. ) 
!................................. ······························ ~~F~P 
~~--~~--~----7~ 
0 10 20 30 40 80 ILA 5 ng equiv.jllask 
0 100 200 300 400 500 AFBP ng equiv./flgsk 
Fig. II.6. 
Monolayer chondrocyte cell cultures prepared from rabbit growth 
plate and articulate chondrocytes were incubated for 20 h in Dul-
becco's medium (Flobio, Courbevoie, France) without foetal calf 
serum. This medium was then replaced with sulphate-free Dulbecco's 
modified medium {MgC1 2 for MgS0 4 ) to which was added 1.5 ~ Ci/ml 
Na2
35
so4 in the presence of different concentrations of ILAs, 
AFBP (SA 1250 ng equiv./mg prot.}, or a mixture of both. 
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teoglycans of rabbit articular chondrocytes in monolayer 
culture produced by ILAs was completely blocked by AFBP 
(fig. II.6.). 
IJ.3.4.c. Sephadex chromatography 
Further evidence for the role of AFBP as a binding pro-
tein for ILAs is presented in fig. II.7 .. AFBP was pre-in-
cubated with 125r-ILAs and chromatographed on Sephadex 
G-150 at neutral pH, resulting in a radioactive peak super-
imposable on the peak of AFBP as determined by ILAs-RRA 
(fig. II.7.a.). No binding of ILAs occurred at pH .......... 2 (fig. 
II.7.b.). When 125 r-ILAs and-AFBP were pre-incubated in the 
presence of unlabeled ILAs, some radioactivity was now 
eluted at the Kd of ILAs (0.7). lOfold increasing the con-
centration of unlabeled ILAs resulted in the elution of 
most of the radioactivity at a Kd of 0.7. Unlabeled insulin 
(500 ng), added to the pre-incubation mixture, did not dis-
place l25r-ILAs from AFBP. 
H.4. Discussion 
Endogenous plasma ILAs is bound to large molecular weight 
proteins, and this binding is easily reversed by exposure 
to acid pH (Guyda et al., 1977}. Gel filtration of amniotic 
fluid in 0.01 M HCl or in 1.0 M acetic acid - two procedures 
which have been uniformly effective in dissociating ILAs 
from binding proteins in plasma - has failed to demonstrate 
the presence of small molecular weight ILAs in human amniot-
ic fluid. When lyophilized amniotic fluid powder was re-dis-
solved in !/20th the original volume and chromatographed in 
0.01 M HCl, t~ereby increasing the concentration 20£old, no 
ILAs-RRA reactivity was observed in fractions where ILAs 
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Fig. II. 7. 
Partially purified AFBP (SA 1250 ng equiv./mg prot.} was chromate-
graphed on Sephadex G-150 (colunm dimensions 0.8 x 50 em) at 4°C. 
0.3 ml fractions were collected. 
_____. RRA activity •--··• Radioactivity. 
a. RRA activity was measured1 after approximately 90 ng equiv. AFBP was 
dissolved and run in 25 mM Tris-HCl, 0.1% BSA buffer (pH 7.4). 
Pre-incubation with 150.000 CPM l25r-·ILAs at 4°C for hour 
in the same buffer resulted in superimposable peaks. 
b. Same quantities as in (a), but run in 0.01 H HCl (pH 2.2), show 
revers al of binding. 
c. In addition to AFBP and l25r-.ILAs as above, 12 ng equiv. un-
labelled ILAs was added to the pre-incubation mixture with buffer: 
25 mM Tris-HCl, 0.1% BSA, pH 7.4. 
d. Idem except 120 ng eguiv. ILAs was added in the pre-incubation 
step. 
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1;-Jould be expected. When incubated and chromatographed in 8 M 
urea, a procedure known to dissociate protein complexes, the 
ILAs-RRA reactivity, although diminished, was again recov-
ered only in the large molecular weight region of the col-
umn. ILAs itself was stable in 8 M urea. It would, there-
fore, seem that the small molecular weight ILAs was absent 
from amniotic fluid and that all the ILAs-RRA activity 
could be accounted for by a moderately large (approximately 
34 x 10 3 MW) acid protein (or proteins) we have termed 
AFBP. AFBP is heat-labile since more than 90% of its RRA 
reactivity was lost by heating to 100°C for 60 min. 
The AFBP identified in amniotic fluid does not appear 
to be a protein-ILAs-complex, but it does display specific 
ILAs binding activity (fig. II.7.). Binding of 125r-ILAs 
by AFBP ~tJas pH-dependentr dissociating at pH 2. Moreover, 
a dose-dependent inhibition of 125r-ILAs binding was ob-
served upon addition of various amounts of unlabeled 
ILAs. No inhibition of 125 r-ILAs binding by unlabeled 
insulin was observed under identical conditions, thus dem-
onstrating the specificity of the AFBP-ILAs interaction. 
To insure that AFBP did not inhibit binding of 125r-
ILAs to its placental receptor by com~eting for the bind-
ing sites, placental membrane binding of l25r-ILAs was 
tested after prior exposure to AFBP. Binding of 125 r-ILAs 
was not inhibited by prior exposure of the membrane to 
AFBP. It would, therefore, appear that the ILAs-RRA activity 
of this protein was due to its ability to bind labeled 
ILAs,thus making it unavailable to the placental receptor. 
Very little has been published on somatomedins or NSILAs 
in amniotic fluid. Bala. et al. (1978) have rei;)orted that 
somatome din, as measured by an in vitro hypophysectomized 
rat cartilage assay, was heterogeneous and consisted of at 
least three components. The major fraction, accounting 
for 86% of the total activity. had an apparent molecular 
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weight of more than 50,000 and did not dissociate into 
smaller molecules in 1% formic acid. The SM bioactivity 
was very lvw at midterm. 
As our work was in progress, Chochinov et al. (1977) 
reported the results of their investigation of an amniotic 
fluid sornatomedin binding protein using a SM-C-RRA. Their 
results closely parallel ours as to molecular weight, iso-
electric point, nondissociation into smaller components 
and presence of the large molecular protein SM as the only 
detectable reactivity in the SH-C-RRA. Direct comparisons 
between our AFBP and Chochinov' s s,r,1-C-RRA reactive amniot-
ic fluid protein (kindly provided by Chochinov) in our 
ILAs-RRA indicated similar behavior. 
AFBP does not cross-react in the INS-RRA, even at a 
concentration of 500 ng equiv./ml, and one would predict 
that it would 1 therefore(be inactive in an insulin bioassay 
system. Such is indeed the case, since our material was 
not active in the epididymal fat pad ass·ay. Furthermore, 
it inhibited ILAs activity in this bioassay system, pre-
sumably by binding ILAs. In addition, complete inhibition 
of sulphation activity by ILAs was observed in cultured 
rabbit chondrocytes. These data suggested that bound ILAs 
is not active tNi th insulin tissue receptors, and they are 
in keeping vri th the observations that "bound insulin" or 
NSILAs is not physiologically active in vivo (Posner et 
al., 1968) or in vitro (Meuli et al., 1978). 
Salmon (1972, 1975) has reported the presence of a so-
matomedin inhibitor in sera of hypophysectomized or starv-
ed rats and has postulated a physiological role for this 
inhibitor in limiting anabolic events, possibly to a great-
er extent than that resulting from the decrease of growth 
hormone release. "Phillips (l979a) has also described a s.o·-
matomedin inhibitor in diabetic rat sera that has a molecu-
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lar weight between 10 and 60 x 10 3 daltons 1 estimated by 
Sephadex chromatography. These inhibitors could account for 
the dichotomy between g"rowth hormone and somatornedin levels 
in human clinical conditions, such as the emotional depriva-
tion syndrome or Kwashiorkor (Van den Brande & Du Caju, 
1974; Van den Brande et al., 1975). The relationship be-
tween AFBP and these other SM inhibitors of plasma remains 
to be clarified. The development of a specific RIA for 
AFBP should facilitate its study. 
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CHAPTER III 
FURTHER PURIFICATION OF AN AMNIOTIC FLUID BINDING PROTEIN 
III.l. Introduction 
From human plasma a number of peptides has been isolat-
ed, termed sornatomedins, all having in common a GH depend-
ency, a growth stimulating effect on cartilage and insu-
lin-like activities (chapter I). These peptides, such as 
Insulin-like Growth Factor (IGF) I and II, Sornatomedin-C, 
Somatomedin-A and Insulin-Like Activity (!LAs), have a mo-
lecular weight of 7,000-9,500 and circulate in serum, com-
plexed to specific SM binding proteins (SMBP) with 150-
200,000 l-1W (Zapf et al., 1975; Hintz and Liu, 1977; Furla-
netto, 1980). In addition, plasma contains an acid-stable 
SM binding protein with + 35,000 MW (Hintz et al., 1981; 
Borsi et al., 1982). 
The precise function of these binding proteins is unclear. 
In addition to being carrier proteins, they may play an im-
portant role in the regulation of the biological effects of 
circulating SM (Meuli et al., 1978; Zapf et al., 1979). 
From human preterm amniotic fluid, an acid-stable SM 
binding protein has been isolated (~ 35,000 MW; pH 4.7), 
inhibiting SM-like activities in various bioassays (Chochi-
nov et al., 1977; Drop et al., 1979). 
The purification procedure, as outlined in our previous 
study (Drop et al., 1979: chapter II), proved to be cumber-
some and time-consuming. The yield was insufficient in 
terms of recovery and purity to allow successful rabbit 
immunization and further characterization studies. 
In this chapter, an improved procedure is described for 
the isolation of AFBP from preterm amniotic fluid, with high 
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speed gel filtration chromatography (HSGFC) and disc-gel 
electrophoresis as the final steps. 
lll.2. Materials 
Human and bovine albumin was purchased from Sigma Chem-
ical Col (St. Louis, Mo.). Sephadex and Sepharose carne 
from Pharrnacia Fine Chemicals (Uppsala, Sweden). 99.5% 
pure Tris was obtained from Koch Light Laboratories (Coln-
brook, U.K.). Dextran-charcoal tablets were bought from 
Becton & Dickerson (Orangeburg, N.Y.). 
Preterrn amniotic fluid was obtained for diagnostic pur-
poses by amniocentesis at a gestational age of 16-22 weeks 
(and kindly provided by prof. dr. M. Nierrneijer, department 
of clinical genetics, Erasmus University, Rotterdam, and dr. 
J. Verjaal, department of genetics, University of Amsterdam). 
The samples were filtered (paper filter Mackeray-Nagel MN 
640), pooled and kept frozen at -70°C until processed. 
Samples,macroscopically showing any blood contamination, 
were discarded. 
111.3. Methods 
11!.3.1. Insulin-like ac1ivi1y 
Insulin-like activity (ILAs) was purified as previously 
described (Posner et al., 1977). Recent studies with radio-
receptor- and radioimmunoassays specific for IGF-I and 
IGF-II indicate that the neutral to slightly acid ILAs 
somatomedin peptide is similar to IGF-II, if not identical 
(Guyda et al., 1981). 
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IJJ.3.2. Amniotic fluid binding protein charcoal binding assay (AFBP-CBA) 
ILAs was iodinated by the chloramine-T method (Posner 
et al., 1977) (procedure kindly performed by W. Hackeng 
Ph.D., endocrine laboratory, Bergwegziekenhuis, Rotterdam). 
AFBP concentrations were estimated by incubation of 100 
~l of sample with 20 1 000 cprn 125 I-ILAs in a final volume of 
500 ~1 with 25 rnH Tris-HCl-1% BSA, pH 7.4. Incubation was 
performed for 2 hours at 4°C. Bound and free 125I-ILAs 
were serarated through addition of 500 vl of a 5.0% char-
coal suspension in Tris-HCl-BSA buffer with 0.01% dextran. 
After 20 minutes, the charcoal was pelleted by centrifuga-
B -NS 
Ba-NS x 100% 
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90 
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50 
.l .2 .3 .4 
Fig. III. 1. 
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• lactoglob 
BSA 
6 8 10 20 30 
mg equiv:/ml 
Amniotic fluid binding protein charcoal binding assay (AFBP-CBA). 
Competitive-dose response curve for a crude AFBP preparation. In 
this figure, the AFBP content of acid-ethanol extract from preterrn 
amniotic fluid is expressed in rng equiv. (protein) /rnl and plotted 
. B -NS 125 aga~nst 100 x 80 -NS' where B0 = I-IGF-II, bound to dextran coa-
ted charcoal in the absence of AFBP, and B = 125 r-IGF-II 1 bound in 
the presence of AFBP. NS = non-specific binding. 
Note: no displacement of HSA, BSA and lactoglobulin B. 
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tion at 3000 rpm at 4°C and the supernatant was discarded. 
125 I-ILAs, adsorbed to the charcoal, was counted in a gam-
ma-spectrometer (Searle, Chicago, Model 1195). Serial dilu-
tions of an impure AFBP solution (acid-ethanol extract, see 
below) were chosen as the standard. The results were ex--
pressed in mg equiv. (protein) /ml. (fig. III.l.). 
Jll.3.3. Protein determination 
The protein concentration was determined by the Bio-rad 
protein assay (Bio-rad Laboratories, Cal.). The Bio-rad 
protein assay is a dye-binding assay based on the differen-
tial color change of a dye in response to various concen-
trations of protein. Bovine albumin was used as the stand-
ard. 
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Sephadex G-150 chromatography of concentrated acid-ethanol extract 
from preterm amniotic fluid. Buffer: 0.01 M HCl. Fractions were 
lyophilized and reconstituted into 25 mM Tris-HC1 1 10 mM MgC1 2 , 
pH 7.4 1 for AFBP-CBA determinations. For purification purposes the 
fractions between Kav 0.4-0.8 were pooled and lyophylized. 
~ = OD 2 80 I = AFBP-CBA activity. 
JJ/.3.4. Acid-ethanol extraction and Sephadex G-150 column chromatography 
Acid-ethanol extraction and Sephadex G-150 column chro-
matography were performed as previously described (Drop 
et al., 1979). Column fractions with highest activity in 
the AFBP-CBA were pooled and lyophilized (fig. III.2.). 
III.3.5. High speed gel filtration chromatography (HSGFC) 
Protein separation was achieved at room temperature on 
two protein analysis (30 ern x 7,8 rom ID) I-125 columns 
(Waters Associates, Milford, Mass.), connected in tandem 
with (0,009 in._ID) stainless steel tubing and zero dead 
volume fittings. The packing material in the columns con-
sisted of 10 ~ silica particles of 12.5 nm nominal size. 
A guard column (2 em x 2 rnm ID), containing packing mate-
rial with 37-53 v silica particles, was connected before 
I 
the I-125 columns. The liquid chromatography assembly from 
Waters Associates (Milford, Mass.) consisted of one solvent 
delivery system (Model 6000 A) and a universal liquid chro-
matograph injector incorporated in the WISP 710 A. UV de-
tection at 280 nrn was performed with a model 440 absorbance 
monitor connected to a W-W recorder. Filtration of solvents 
was carried out with a pyrex filter holder and 0.5 ~ fil-
ters from Millipore (Bedford, Mass.). Protein fractions were 
dissolved in 25 mM Tris-HCl,pH 7.0, and injected in 0.1-1 
mg protein aliquots. The same buffer, at a flow rate of 0.5 
ml/min.,was used as mobile phase. The fractions containing 
AFBP were pooled and concentrated by centriflo membrane 
ultrafiltration (Amicon, Lexington, Ky.). 
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Ill.3.6. Disc-gel polyacrylamide gel electrophoresis 
Disc-gel polyacrylamide gel electrophoresis was carried 
out at 4°C, with a 20% acrylamide separative gel, a 2.5% 
acrylamide concentrating gel and a continuous buffer sys-
tem of Tris-glycine-HCl, pH 8.3. The proteins were eluted 
by a modification of the method described by Mendel-Hartvig 
(1982): following electrophoresis the gels (0.5 x 10 ern) 
were sliced into 0.5 em fractions. These were reapplied on 
a separative gel. A stacking gel was formed on top of the 
sample gel. The tubes were sealed with dialysis membrane 
(MW cutoff at 10,000). When the poles were reversed, the 
protein was electrophoresed through the stacking gel in an 
overlay of Tris-glycine buffer. The overlay was removed 
with a syringe, pooled, dialysed and concentrated in a 
Micro-Prodicon negative pressure micro protein dialysis 
concentrator (Bio-Molecular Dynamics, Beaverton, Ore., USA). 
Ill.3. 7. Polyacrylamide slab-gel electrophoresis 
Il1.3.8. Analytical polyacrylamide ampholine isoelectric focusing 
Both polyacrylamide slab-gel electrop~oresis, with and 
without sodium dodecyl sulphate (SDS), at pH 7.0 1 with a 
12% separative gel and a 4% concentrating gel, and analyt-
ical polyacrylamide ampholine is?electric focusing, with 
ampholine PAG plates (pH 4-6.5), were carried out on an 
LKB 2117 multiphor system according to the manufacturer's 
directions (LKB, Stockholm, Sweden). 
III.3.9. Affinity chromatography 
Affinity chromatography vras performed on a Concanavelin 
A Sepharose column (2. 7 x 11 em) in 20 mN. Tris-HCl, o.S mM 
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NaCl, pH 7.4 buffer. The proteins were eluted with methyl-
alpha-D~-mannoside (0. 2 M) in the starting buffer. 
/J/.3.10. Double immunodiffusion 
Double immunodiffusion in gel was carried out by the 
method of Ouchterlony (1962), with gels prepared from 1.5% 
agar in 0.4 M Tris-barbital buffer, pH 8.8. 
Il1.3.11. Staining procedures 
III.J.ll.a. Coomassie brilliant blue stain 
Gels were soaked for 3 hours in 0.25% (W/V) Coomassie 
blue R-250, 45% (V/V) methanol, 10% acetic acid, then de-
stained in 10% methanol, 7% acetic acid. 
III.3.ll.b. Silver stain 
Gels were soaked for 1 hour in 30% methanol, 10% TCA and 
3.5% sulphosalicilic acid, washed thoroughly in 15% metha-
nol, then soaked in 5% glutardealdehyde and washed in 15% 
methanol and distilled water. The gels were stained with 
a solution of 0.7% AgN0 3 in 0.08% NaOH- 1.4% NH 40H for 
30-40 minutes. After washing in distilled water, the stain-
ing was terminated by incubation of the gels in 0. 0.01% cit-
ric acid- 0.007% formaldehyde for 10 minutes. 
II!.3.12. Binding studies 
Partially purified AFBP (Sephadex G-150 purified mate-
rial, step 3, table III.l.), 100 ~g equiv. prot./tube, was 
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pre-incubated for 2 hours at 4°C in 200 vl 10 mM Tris-HCl-
0.5% BSA buffer (pH 7.4) with 100 "l ILAs (IGF-II) at var-
ious dilutions (0, 25, 50, 75, 100, 500, 750 ng equiv./ml). 
100 vl of labeled SM-C/IGF-I o~ IGF-II respectively 
(+ 25,000 cpm) then was added. Following a further 2-hour 
incubationl500 vl charcoal solution (1% norit A+ 0.1% 
dextran T 250 in 10 rnM Tris-HCl, pH 7.4) was added. After 
20 minutes_, the charcoal was pelleted by centri:Zugation at 
3000 cpm at 4°C for 30 minutes and the supernatant was 
discarded. The pellet was counted in a gamma-spectrometer 
(Packard,Model 5120). 
UI.4. Results 
Il/.4.1. AFBP charcoal binding assay (AFBP-CBA) 
As the SM binding proteins present in preterm amniotic 
fluid are predominantly, but not exclusively small molecular 
weight proteins (30-50,000 MW range) (see fig. III.2.), 
the AFBP charcoal binding assay could be used as a simple 
and effective method to detect and quantitate a protein 
with an apparent molecular weight of 35-40,000 and SM {ILAs 
or IGF-II) binding activity. An impure AFBP solution (acid-
ethanol extract, step 2, table III.1.) was designated as the 
standard. As shown in fig. III.l., no cross-reactivity was 
observed with either human or bovine serum albumin and lac-
toglobulin at a concentration of 1-10 rng/ml. 
III.4.2. Purification 
The purification steps are given in table III.l .. During 
the first step, acid-ethanol insoluble proteins, the large 
molecular weight SM binding proteins included, were pre-
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Table III.l. 
Purification schema 
mean specific estimation 
activity (CBA) of protein 
"g equiv. /mg prot. recovery 
% 
l. AF pools (n = 5 I 1 '4 41 10 0 
2. Ethanol-extract 
'pools (n = 11 I 1 ,o 6 4 52 
3. Sephadex G-150 
pooled fractions 
(n = 7 I 15 ,741 28 
4. HSGFC I + 
" (n = 3 I 57,800 3.5 
HSGFC III 
(n = l I 202,300 1.5 
5. Disc-gel 
electrophoresis 
? ? 
cipitated. The specific activity (SA) did not improve dur-
ing this initial step, probably due to the fact that all 
SM binding proteins react in the charcoal binding assay 
in unpurified amniotic causing spuriously high values 
fluid. However, Sephadex G-150 column 
III.2.) resulted in a slight increase 
chromatography (fig. 
of SA. The effect of 
repeated HSGFC on the purification is illustrated in fig. 
III.3.a., b., c. ,d .• 
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AFBP-CBA 
/--19 equiv/ml 
a 
3 
b 
0,6 
0.4 
0.2 
' 
0.3 
0.2 
0. I 
d 
Fig. III.3.a. 
70 
min. 
Sephadex G-150 chromatographed material (see fig. III.2.) was sub-
jected to high speed gel filtration chromatography (HSGFC I). 
--= 00280 , I= AFBP-CBA activity, •= HSA, fl.= lactoglobulin B. 
Fig. III.3.b.3.c. 
Fractions •,.,rith highest AFBP-CBA activity Here reapplied twice 
(HSGFC II, III). 
Fig. III.3.d. 
Note: follo•,.,ring HSGFC III_. no protein extinction (oo 280 ) at the 
elution volume of HSA with UV detection at highest sensitivity. 
This procedure resulted in a further 30fold purification. 
As albumin, through the Ouchterlony immunodiffusion tech-
nique, was found to be still present as a contaminant (data 
not shown), fractions with highest activity in the AFBP-
CBA were pooled and the freeze-dried material was subjected 
to disc-gel polyacrylamide gel electrophoresis. Fractions 
showing AFBP-CBA activity, but devoid of human albumin as 
determined by the Ouchterlony immunodiffusion technique, 
were pooled (fig. III.4.). AFBP was recovered by electropho-
retic concentration according to a procedure described by 
AFBP-CBA 
mg equiv/ml 
0.3 
0.2 
0.1 
0 
protein 
~g/ml 
30 l 
20 I 
1: j ,......... 
0 2 
Fig. III.4. 
4 6 8 10 12 14 16 18 
Disc-gel polyacrylamide gelelectrophoresis. Protein fractions were 
recovered by a modification of the method described by Mendel-
Hartvig (see materials). In this figure, the gel electrophoresis of 
Sephadex G-150 purified AFBP is shown because of limited supply of 
HSGFC purified material. At a gel length of~ 4 cm,highest protein 
concentrations are due to HSA, whereas highest AFBP-CBA activity 
is recovered at a gel length of ~ 8 em. 
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Mendel-Hartvig (1982), with a modification as outlined in 
Materials and Methods. An estimation of protein recovery is 
presented in table III.! .. It should be noted, however, that 
the capacity of the last two purification steps was very 
limited (see also appendix 1, chapter III). Therefore, an 
insufficient amount of purified AFBP was available for 
measuring charcoal binding activity and calculating specif-
ic activity. Priority was given to characterization stud-
ies (see below). 
Ul.4.3. Binding studies 
To determine the binding affinity of AFBP to IGF-I and 
IGF-II, a competitive binding assay was performed. Very 
poor displacement of labeled IGF-I and IGF-II by ILAs of up 
to 500 ng equiv./ml was found (studies kindly performed by 
H.J. Guyda, McGill University, Montreal, Canada). Partially 
purified AFBP (~ 250 ~g protein; step 3, table III.l.) was 
cross-linked with 125 I-SM-C in the presence of disuccinimi-
dylsuberate (DSS) and run on polyacrylamide gels in the 
presence of unlabeled SM-C (100 and 800 ng respectively). 
Predominant binding took place at a Kf corresponding to an 
apparent molecular weight of 39,000. No displacement occur-
red in the presence of 800 ng SM-C (studies kindly perform-
ed by J. D'Ercole, University of North-Carolina, Chapel 
Hill, USA). Due to this lack of displacement, it was not 
possible to calculate an affinity constant by Scatchard 
analysis. 
II/.4.4. Bioassays 
Inhibition of IGF-I/SM-C activity by partially purified 
AFBP (step 3, table III.1.) was demonstrated by Z. Laron 
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(Beilinson University, Tel Aviv, Israel) using a chick em-
bryo cartilage bioassay (Silbergeld et al., 1981) (data 
not shown). Van Buul and Van den Brande (State University 
of_ Utrecht, the Netherlands) registered inhibition of SM 
(partially purified SM and plasma SH activity) in their 
porcine costal cartilage bioassay (fig. III.S.). 
SM (mU) 
400 
300 
200 
100 
..................................................................... 
0 
0 330 1000 3000 
AFBP (/Jg equ;v) 
Fig. III.S. 
Partially purified AFBP (step 3, table III.l. ), at various concen-
trations (abscissa), was added to medium {••''"'"), to 0. 4 U plasma 
(--), 0.2 U plasma (--} and to 0.2 U plasma+ 0.15 U of 
a somatomedin preparation (-----). AFBP inhibits SM activity (or-
dinate) measured in the porcine costal cartilage SM bioassay (Van 
den Brande and du Caju, 1974) (kindly performed by S. van Buul-
Offers, Utrecht). 
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fll.4.5. Characterization 
Disc-gel purified AFBP was subjected to analytical slab-
gel (SDS) polyacrylamide gel electrophoresis. Following a 
silver staining procedure of the gel, only one band was 
identified (fig. III.6.). 
A previously determined isoelectric point of 4.7 (Drop 
et al., 1979) was confirmed by analytical isoelectric fo-
cusing. Disc-gel purified AFBP was run on an LKB Ampholine 
PAG plate (pH range of 4-6.5). Following silver staining 
of the gel, 3 bands in the narrow pH range of 4.7-4.9 were 
identified (fig. III.7.). 
Disc-gel purified AFBP was subjected to analytical ul-
tracentrifugation (kindly performed by W. van Noort and 
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a b c d e f g 
Fig. III.6. 
Analytical slabgel SDS polyacrylamide gelelectrophoresis of AFBP 
containing fractions at various stages of purification. Applied 
amount of protein 1-10 ~g per slot. 
a = HSA; b = lactoglobulin B; c = amniotic fluid; d-g = purifica-
tion step 2-5 (table III. l. ), 
AFBP is visible following step 3 (gel e). After disc-gelelectropho-
resis one band is shown (gel g). The gels were silver stained. 
prof. dr. H.G. van Eijk, department of chemical pathology, 
Erasmus University, Rotterdam). The initial studies were 
inconclusive, due to low protein concentration of the sam-
ple. Partially purified AFBP (step 3, table III.!.) was 
applied on a Concanavalin A Sepharose column. Following 
elution with methyl-alpha-D-rnannoside, AFBP activity was 
recovered, which suggested AFBP to be a glycosylated pro-
tein. 
a b c d e f g 
Fig. III.7. 
Analytical iso-electric focusing (LKB Ampholine PAG plates, .pH 
4-6.5). 
a = HSA; b = lactoglobulin B; c ~ amniotic fluid= d-g = purifica-
tion step 2-5 (table III.l.). 
Disc-gel purified AFBP is visible as multiple bands within a pH 
range of 4.7-4.9, gel 9· The gels were silver stained. 
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The stability of AFBP was tested by subjection of par-
tially purified AFBP (step 2, table III.l.) at various dilu-
tions to a temperature of 20°C, 60°C and 100°C and to a pH 
range of 1.0-11. Details of this study are given in appen-
dix 2, chapter III. The results indicate that the SM bind-
ing activity is maintained regardless of temperature and 
pH. 
III.S. Discussion 
Amniotic fluid binding protein was detected when in pre-
term amniotic fluid in an SM placenta membrane radiorecep-
torassay activity was found which could not be attributed 
to small molecular weight SM (Chochinov et al., 1976; Drop 
et al., 1979). At first, AFBP activity was determined in 
this RRA, but because of nonparallel displacement, quanti-
tative results could be taken as an approximation only 
(Drop et al., 1979; chapter II). Preterm amniotic fluid 
mainly (but not exclusively) contains small molecular 
weight SM binding protein(s). Therefore, a simple and di-
rect, albeit crude way of quantitation of an SM binding pro-
tein was found in the charcoal binding assay, similar to 
previously described mGthods for the determination of 
SM-C/IGF binding activity in serum (Moses et al., 1979; 
Zap£ et al., 1980; Hintz et al. 1 1981). As is shown in 
fig. III.1., the sensitivity of the assay was limited. No 
further specific binding occurred with standard solutions 
of crude AFBP containing more than 10 rng protein/rnl, pos-
sibly due to the high protein content and decrease of ac-
cessible binding sites (Daughaday et al., 1982a). 
The purification of AFBP from preterm amniotic fluid 
was hampered by the following circumstances: 
1) The AFBP content in preterm AF in terms of microgram 
protein is very low as, during disc- or slab-gel poly-
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acrylamide gel electrophoresis of ethanol extract and 
Sephadex G-150 purified AFBP (step 2 and 3, table III.l.), 
no stainable protein bands were visible even with a 
very sensitive silver staining procedure, whereas SM 
pinding activity could be demonstrated. 
2) As far as the last purification step, albumin remained 
present and substantial losses could be accounted for by 
shoulder fractions and trailing (fig. III.2., III.3.). 
As both AFBP and albumin have an isoelectric point 
of 4.7-4.8, separation had to be based upon differences 
in chromatographic behavior due to molecular size. 
Therefore 1 high speed gel filtration chromatography 
proved to be a valuable tool in the purification (see 
also appendix 1, chapter III). 
3) It is likely that low AFBP recovery during the final 
purification steps was also caused by nonspecifiC at-
tachment of AFBP to tubing, dialysis membrane, glass-
ware etc. On the other hand, one could speculate about 
an interaction between HSA and AFBP maintaining the sta-
bility of AFBP, as has been demonstrated for pre-albu-
min and retinol binding protein (RBP) (Kanai et al., 
1968). Both binding proteins retained their binding po-
tential since the pre-albumin-thyroxin binding as well 
as the RBP-Vit A binding were found to be independent 
of this protein-protein interaction (Raz & DeWitt Good-
man, 1969). 
Purified AFBP migrated as a single band in analytical 
polyacrylamide gel electrophoresis systems with an apparent 
molecular weight of 35-40,000. 
AFBP probably is a glycoprotein as it is recovered 
from a Concanavelin A column. Therefore, the molecular 
weight determination may be subject to error. The multiple 
bands, found during analytical polyacrylamide ampholine 
isoelectric focusing at a pH range of 4.7-4.9, may repre-
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sent heterogeneity in the degree of glycosylation of the 
AFBP molecule. 
As discussed in chapter II, AFBP is acid-stable. In 
appendix 2, chapter III, it is outlined that the SM bind-
ing activity is heat-stable, irrespective of the pH. 
In a competitive binding assay in which labeled IGF-I 
and IGF-II were tested, AFBP appeared to be an SM binding 
protein with low affinity and such high capacity that for-
mal Scatchard analysis proved unsuccessful. 
Thusfar, the binding proteins for peptides, which have 
chemically been fully characterized 1 are the MSA carrier 
protein, purified from a rat liver cell line (Knauer et al. 
1981), and the EGF binding protein, purified from homage-
nates of submaxillary glands of male albino mice (Taylor 
et al., 1974). The MSA carrier protein consists of two 
different,non-covalently linked protein chains with an ap-
parent molecular weight of 30,000 and 31,500. The EGF 
carrier protein has a molecular weight of 30,000,an iso-
electric point of 5.6 and possesses arginine-endopeptidase 
activity. 
Recently, two SM binding proteins with an apparent molec-
ular weight of approximately 46,000 and 30,000 were demon-
strated in human serum (Morris and Schalch, 1982). These 
proteins appeared to be breakdown products of an alkaline-
treated, 60,000 MW SM binding protein complex. Hintz de-
scribed an unsaturated form of an SM binding protein with 
a molecular weight of 35-40,000 (Hintz et al., 1981). 
Binoux suggested the existence of two binding proteins in 
culture media of rat and human liver cells, each with a 
molecular weight of approximately 40,000, but with dif-
ferent affinity for IGF-I and IGF-II (Binoux et al., 1982). 
As these serum binding proteins share several biological 
characteristics with AFBP, it would be of great importance 
to prove or disprove their homology. 
The purification of AFBP permitted the immunization of 
64 
rabbits and the raising of specific antibodies against 
AFBP. The development of a radioimmunoassay for AFBP is 
presented in chapter IV. 
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APPENDIX !,CHAPTER III 
HIGH SPEED GEL FILTRATION CHROMATOGRAPHY 
App. 1, 111.1. Introduction 
Gel filtration chromatography (GFC) has been widely used 
to separate proteins of varying molecular size. In the meth-
ods used to obtain these separations, cross-linked dex-
trans, polyacrylamide and agarose gels have been applied. 
With the development of rigid microparticulate packings, 
such as dial-modified silica gels (fig. app. 1, III.l.), 
with both low adsorptivity and low hydrophobicity, rapid 
separation, largely based on the effective size and shape 
of the protein, has become feasible (Majors, 1980). Hence, 
~- OH + (R0)3Si(CH2 ) 3 0CH 2 ~~H2 
Silica 10 - 50 nm 
Fig. app. l, III.l. 
Reaction equation used in the preparation of the dial-modified si-
lica gel (Majors, 1980). 
this method has become known as high performance (speed)-
size exclusion {molecular partition)-gel filtration. 
As the parameters determining the extent and effective-
ness of the separation may differ from one protein to the 
other (see table app. 1 7 III.l.), we performed a limited 
number of experiments in order to determine the most effec-
tive setup for the further purification of partially puri-
fied AFBP. 
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App. I, lll.2. Materials and methods 
Human, bovine and ovine albumin and lactoglobulin B were 
purchased from Sigma Chemical Co. (St. Louis, Mo.). I-125 
carne from Radiochemical Centre (Arnersharn, U.K.). Filtra-
tion of solvents was carried out with a pyrex filter hold-
er and 0.5 ~filters from Millipore (Bedford, Mass.). 
Protein fractions were dissolved in 25 rnr-1 Tris-HCl, 10 
mM MgC1 2 , pH 7.4,unless stated otherwise. Gel filtration 
was performed at room temperature on one and,later,on two 
I-125 protein columns (30 em x 7.8 mrn ID) (Waters Ass., 
Milford, Mass.). The packing material in the columns con-
sisted of 10 ~ silica particles of 12.5 nrn nominal size, 
giving the column exclusion limits of 2,000 to 80,000 MW. 
A guard column (2 em x 2 mm ID) contained packing material 
with 37-53 w silica particles. The liquid chromatography 
assembly from Waters consisted of one solvent delivery sys-
tem (Model 6000 A) and a universal liquid chromatograph 
injector incorporated in the WISP 710 A. Unless stated dif-
ferently, UV detection at 280 nm was done with a Model 440 
absorbance monitor, connected to a W/W recorder (Scientif-
ic Instruments, Basel, Switzerland). 
App. 1, 111.3. Results 
The influence of various parameters on the resolving 
capacity of high speed gel filtration chromatography of 
human serum albumin (67 1 000 MW) 1 ovalbumin (43 1 000 MW) and 
lactoglobulin B (35 1 000 MW) was investigated 1 before amniot-
ic fluid binding protein (AFBP) fractions were tested. 
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0 
- "'OD2oo 
.o\. = HSA 
¢=ovalbumin 
4 8 
Fig. app. 1, III.2. 
12 16 
a. TO mM Tris-HCI (pH 7.4) 
A-¢ =Omin. 
b. 25 mM Tris-HCI, 10 mM MgCI 2 (pH 7.4) 
+ 0.01 M NaCI 
•- o = 0.6 min. 
c.- +0.1 M NaCI 
.o\.-¢"'0.8min. 
d. - + 0.25 M NaCI 
A-¢ =0.85min. 
20 
min. 
The effect of varying the flow rate of the mobile phase (25 mM 
Tris-HCl, 10 mM MgC1 2 , pH 7.4) on the retention time of human serum 
albumin (HSA; MW: 67,000) and ovalbumin (MW: 43,000}. 50 ~1 of a 
1 mg/ml solution of each protein was injected simultaneously on a 
I-125 protein column (Waters Ass., Milford, USA). 
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70 
-= 00280 
_.., HSA 
0= ovalbumin 
NoCI (M) 
0.4] 
0.2 ... ----
0 ---------------
---
1 
0 4 8 12 
Fig. app. 1, III. 3. 
0 
16 
e.-+ 0.5 M NoCI 
.A-0 "'0.8 min. 
f.-+ 0.75 M NoCI 
... -o =0.8min. 
g.-+l.OMNoCI 
.A-0 = 0.9 min. 
h.-+ 1.5 M NoCI 
.A-¢=0.9min. 
i.-+0 0.5MNoCI 
•-O =0.8min. 
20 
min. 
The effect of varying the ionic strength of the mobile phase on 
the retention time of HSA and ovalbumin. Flow rate of mobile phase 
0.5 ml/min. Protein concentrations and column conditions as in 
fig. app. 1, III.2. 
-= 00280 
•= HSA 
¢= ovolbumin 
0 4 8 12 
24 
16 
28 
a. flow: 1.0ml/min. 
•-<> =0.3 min. 
b. flow: 0.5 ml/min. 
•-o "'1.0 min. 
c. flow: 0.4 ml/min. 
•-<> = 1.4 min. 
d. flow: 0.2 ml/min . 
.~o.-<> = 3.6 min. 
7l 
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0 
-~ OD2ao 
4 ~ HSA 
A= lactoglob. 
24 
Fig. app. 1, III.4. 
28 
a. l [-125column 
Ji..-l:J.. =3.2 min. 
b. 2 1-125 columns 
.A.- A:::::: 5.7 min. 
40 44 
min. 
The effect of column length on the retention time of HSA {MW: 
67,000) and lactoglobulin B (MW: 35,000). Flow rate 0.5 ml/min. In-
jected sample volume 50 lll {l mg protein/ml). 
App. l, III.3.1. Influence of flow rate 
10 ~1 of a solution containing HSA (0.5 rng/ml} and ovalbu-
min (0.5 mg/rnl) was injected. The effect of varying the 
flow rate of the mobile phase (25 mM Tris-HCl, 10 mM MgCl 2 , 
pH 7.4) between 0.2-1 ml/rnin. on the retention time of the 
proteins is shown in fig. app. l,III.2 .. Separation in-
creased with decreasing flow rate. For practical purposes 
a flow rate of 0.5 ml/rnin. was chosen during subsequent 
testing. 
App. 1, I!I.3.2. Influence of ionic strength 
With low ionic strength (10 mM Tris-HCl, pH 7.4) no separa-
tion of HSA and ovalbumin occurred (fig. app. 11 III.3.). 
When the ionic strength was increased either by added NaCl 
(O.Ol-1,5 M) or by a gradient (0-0.5 M), the delta (A) elu-
tion time of the two proteins increased only slightly from 
0.6 to 0.9 minutes. Therefore,the addition of NaCl to the 
mobile phase buffer was concluded to be of no advantage. 
App. l, IJI.3.3. Influence of column length 
As shown in fig. app. 1, III.4., doubling of the retention 
time of HSA and lactoglobulin occurred when 2 Waters I-125 
columns, preceded by a guard column, were applied. The conse-
quent peak broadening and the time increase of the chroma-
tography were quite acceptable. 
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App. 1, ll/.3.4. Influence of organic solvent 
As AFBP was found to be unstable in various organic solvent 
solutions (containing methanol, propanol) and these sol-
vents could interfere with the direct measurement and proc-
essing of AFBP, no organic solvents were tested. 
In all subsequent studies and in the purification of 
AFBP, 2 protein analysis I-125 columns were used, connected 
in tandem and preceded by a guard column. The mobile phase 
(25 rnM Tris-HCl, 10 rnM MgCl 2 , pH 7.0) had a flow rate of 
0.5 ml/min, 
App. 1, ll/.3.5. Recovery 
When partially purified AFBP was applied on two I-125 
columns, the recovery of protein was 85-90%. 
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em peak height 
8 
4 
0 
Fig. app. 1, III.S. 
2.5 
~g/injectio~ 
50 ~I 
Correlation between peak height of oo280 extinction and sample 
protein concentration. HSA dilutions (50 ~1 aliquots) were injec-
ted on one I-125 protein column. Flow rate mobile phase l ml/min. 
a 
cpm 
3000 
-"" ODzso 
• ~ HSA 
LJ."" lcctoglob. 
2000 
1000 
0 
b 
c 
0 4 8 
Fig. app. 1, III.6.a. 
12 16 20 24 28 
min. 
Determination of void volume (Vo, dextran blue) and total volume 
(Vt) (Na-rl25) of one I-125 protein column. Flow rate 0.5 ml/min, 
(Tris buffer). 
Fig. app. 1, III.6.b. 
Elution profile of preterm amniotic fluid. Sample volume 50 ~l 
(protein concentration 3. 8 mg/ml) (biorad) . Flow rate 0. 5 ml/min. 
(Tris buffer). 
Fig. app. 1, III.6.c. 
Elution profile of acid-ethanol extract of preterm amniotic fluid 
(see table III.l.). Sample volume 50 J-ll (protein concentration 
7 mg/ml). Flow rate 0.5 ml/min. 
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App. 1, !!1.3.6. Quantitative analysis 
As shown in fig. app. 1, III.S., there is good correla-
tion between the maximal extinction of 280 nrn and the pro-
tein concentration of the applied sample. 
App. 1, !1!.3.7. HSGFC in the purification of AFBP 
The effect of high speed gel filtration chromatography 
of preterm amniotic fluid and acid-ethanol extract is 
shown in fig. app. 1, III.6. (step 1 and 2, table III.l.). 
App. 1, !11.4. Discussion 
Two modes of interaction between proteins and a protein-
separating column, such as the Waters I-125 column, deter-
mine the effectiveness of the separation (Majors, 1980; 
Scott, 1980). 
One is the ionic attraction or repulsion of ionizable side 
chains of the protein and accessible,negatively charged si-
lanol sites on the surface of the silica-based column pack-
ing material. Therefore,increasing the ionic strength of 
the buffer will minimize the electrostatic interaction. An 
ionic strength of at least 20 mM was found to be necessary 
to obtain a separation of HSA and ovalbumin (fig. app. 1, 
III.2.). However, with further increment of the ionic 
strength,the advantage of improved separation did not out-
weigh the disadvantage of a high salt concentration in the 
protein fractions. 
The other mode of interaction is the hydrophobic attrac-
tion of the alkyl-bonded phase of the silica column to non-
polar, aminoacid residues on the surface of the protein mol-
ecule. An organic solvent, such as methanol, ethanol or 
7G 
propanol, can be effective in reducing these interactions, 
thereby improving the recovery. 
As illustrated in table app. l,III.l., there is quite 
some variation in regard to the constitution of the mobile 
phase, its ionic strength, the presence or absence of an 
organic solvent and the optimal flow rate. With a 20 mM 
Tris-HCl buffer, HSGFC proved to be a very useful and rapid 
method for the purification of amniotic fluid binding pro-
tein. 
As most proteins are sensitive to temperature, it is a 
disadvantage to perform the HSGFC procedure at room tem-
perature, since it proved to be technically impossible to 
cool the complete tubing system. The guard column has an 
important protective function. But even after filtration 
and chromatography of relatively pure protein solutions, 
discoloration of the proximal part of the first column 
occurred and the systemic pressure increased. Furthermore, 
the gel volume was noted to decline in time, creating a 
dead space and chromatographic changes. The reason for 
this phenomenon is not well understood, but it is likely 
the result of silica being soluble in water and siloxane 
bonds being labile during basic hydrolysis. "As long as 
silica based packings are used at high pHs, high buffer 
strength and at elevated temperatures, shortened column 
lifetimes will have to be accepted 11 (Majors, 1980). 
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APPENDIX 2,CHAPTER III 
THE EFFECT OF TEMPERATURE AND PH ON 
THE STABILITY OF AFBP 
App. 2, Ill.l. Introduction 
The heat-lability of acid-stable sornatornedin inhibitory 
activity of starved rat serum with a presumed molecular 
weight of 27-40,000 depends upon pH and the degree of di-
lution (Salmon et al., 1983). 
We investigated the effect of temperature and pH on 
the stability of amniotic fluid binding protein (AFBP), by 
determing SM binding capacity and AFBP immunoreactivity in 
various dilutions of partially purified AFBP. The results 
indicate that AFBP is heat-stable, irrespective of pH. 
App. 2, Ill.2. Materials, methods and results 
Impure AFBP (acid-ethanol extract, step 21 table III.l.) 
was obtained, as outlined in chapter III, and dissolved in 
10 mM Tris-HCl,pH 7.4,in 3 dilutions: 20 1 10, and 2 rng/rnl 
(dry weight). All samples were determined in duplicate. 
Details of the charcoal binding assay (CBA) are described 
in chapter III. The methodology of the radioimmunoassay 
(RIA) is given in chapter IV. The correlation between the 
standards, used in both assays, is given in fig. app. 2, 
III.l .. Total protein content was determined by the bio-rad 
method. 
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pg/ml 
15 
12 
9 
6 
3 
• 
• 
• 
0.5 
Fig. app. 2, III.l. 
• 
• 
1.0 1.5 2.0 2.5 
pg equi4ml 
Correlation standards used in charcoal binding assay (CBA) and ra-
dioimmunoassay (RIA). 
Total protein content was measured (Biorad) in dilutions of acid-
ethanol extract (step 2, table III. 1. ), used as standard for the 
CBA (ordinate), and in dilutions of Sephadex G-150 purified materi-
al (step 3, table III. 1. )1 used as standard for the RIA (abscissa). 
App. 2, ll/.2.1. Effect of pH 
To 0.1 ml of the AFBP solutions, 0.4 rnl Tris-HCl, pH 
7.4 buffer (control), 0.1 rnl 0.3 M HCl or 0.1 rnl 0.3 M NaOH 
was added. After 3 hours the samples were neutralized with 
0.3 M NaOH and 0.3 M HCl respectively at 37°c and assayed. 
Results are given in fig. app. 2, III.2., indicating no 
effect of pH on AFBP activity in CBA and RIA. 
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AFBP-R1A 
1.6 
a b c 
1.2 
0.8 
0.4 
20 1) ')') 4) 5) 6) ')') ') 4) ') ') 
12 
12 
8 
4 
Fig. app. 2, III.2. 
Effect of temperature and pH on AFBP. 
A. 20, 10 1 and 2 mg of lyophilized acid-ethanol extract (step 2, 
table III.l.) were dissolved in Tris-HCl, pH 7.4 buffer, and 
kept at room temperature for 3 hours ( 0), at 60°C for 1 hour 
([]) and heated at 100°C {§§]) for 10 minutes. 
B. 10 mg lyophilized acid-ethanol extract (step 2, table III.l.) 
was dissolved in a buffer, pH range of 2.5-8.5, and heated for 
l hour at 60°C (Q). 
l) pH 8.5 2) =pH 6.5 31 pH 5.5 4) pH 4.5 5) pH 3. 5 
6) =pH 2.5 
C. 10 mg lyophilized acid-ethanol extract (step 2, table III.l.} 
was dissolved in a buffer, pH range of 2.5-8.5, and heated for 
10 minutes at l00°C (~). 
1)- 6) see fig. app. 2, III.2. B. 
All fractions were neutralized (pH 7.4) before assaying in AFBP-
RIA and AFBP-CBA. 
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App. 2, IJ/.2.2. Effect of temperature 
To 0.1 ml of the AFBP solutions, 0.4 ml of Tris-HCl, pH 
7.4 buffer, was added. The tubes were either kept at room 
temperature for 3 hours or sealed, placed in a water bath 
at 60°C for l hour or at 100°C for 10 minutes. They were 
centrifuged and the supernatant was assayed. The results 
are given in fig. app. 2, III. 2. , indicating no effect of 
heating at 60°C for 1 hour or boiling at 100°C for 10 min-
utes on AFBP activity determined by CBA and RIA. 
App. 2, IJI.2.3. Effect of temperature and pH 
To 100 wl of the 10 rng/ml AFBP solution, solutions of 
0.3 M NaOH and 0.3 M HCl were added, with a pH of 8.5, 6.5, 
5.5, 4.5, 3.5 and 2.0 respectively. The tubes were sealed 
and placed in a water bath at 60°C for 1 hour or at 100°c 
for 10 minutes. The tubes were centrifuged and the superna-
tant was assayed. The results are given in fig. app. 2, 
III. 2 ., and indicate no effect of heating on AFBP activity 
at a pH range of 2. 2 - 8. 5. 
App. 2, 111.3. Discussion 
Previousl~we reported on the loss of radioreceptorassay 
activity following heating at 100°C of partially purified 
AFBP (Drop et al., 1979, chapter II). However, the present 
study clearly indicates that heating at 60°C for 1 hour or 
at 100°C for 10 minutes at a range of pH 2.2 - 8.5 does 
not destroy SM binding capacity or immunoreactivity of AFBP. 
The heating appeared to result in slightly higher CBA 
activity. Evaporation of solvent is an unlikely explanation, 
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as the tubes were sealed during the heating procedure and 
centrifuged before assaying. In addition, RIA activity re-
mained unchanged. The heating may have caused an ultra-
structural change of the protein, resulting in the exposure 
of an increased number of binding sites. We conclude that 
the effect of temperature and pH on AFBP and an SM inhibi-
tory activity of starved rat serum differ only in that, in 
the latter, activity is lost upon heating at !00°C at pH 
5. 5. 
A practical consequence of this study is that the heat-
stability of AFBP allows heating of native serum prior to 
the determination of AFBP by RIA in native serum. Especial-
ly at low dilutions of whole serum, this procedure could 
lead to an improvement of the sensitivity of the assay, as 
will be outlined in chapter v. 
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CHAPTER IV 
DEVELOPMENT OF A RADIOIMMUNOASSAY FOR AN SM BINDING 
PROTEIN IN AMNIOTIC FLUID 
IV.l. Introduction 
Somatornedin (SM) is a small molecular weight, growth 
hormone dependent 1 growth stimulating protein, thought to 
be involved in the humoral regulation of fetal growth. Evi-
dence stems from the fact that specific receptors for ra-
diolabeled SM have been detected in numerous fetal tissues 
and that fetal cells produce somatomedins endogeneously 
(D'Ercole et al., 1980b; Hill and !1ilner, 1981). Although 
levels of SM activity in cord blood correlate with fetal 
and early postnatal growth, they generally are discordant-
ly low in comparison with GH levels, which exceed postna-
tal values (Brinsmead and Liggins, 1978; Sara and Hall, 
1980). In amniotic fluid SM is barely detectable by bio-
assay (Anderson et al., 19741 Bala et al., 19761 Bala et 
al., 1978; Hill and Milner, 1981}. 
With an SM radioreceptorassay, a heat-labile, acid-sta--
ble SM binding protein was demonstrated (Chochinov et al., 
1977; Drop et al., 1979). This binding protein, with a mo-
lecular size of± 35,000 and pi 4.7, inhibited SM bioactiv-
ities in various bioassays (Drop et al., 1979}. The levels 
of this binding protein in amniotic fluid were highest at 
mid gestation, and their subsequent decrease correlated 
with fetal renal maturation, suggesting a fetal origin of 
the binding protein (Chochinov et al. , 19 76) . 
In chapter III, we have described an improved procedure 
for the purification of this amniotic fluid binding protein 
(AFBP). In this chapter, we report on the development of a 
specific radioimmunoassay for AFBP (AFBP-RIA). 
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This AFBP-RIA enabled us to: 
a) measure AFBP directly in preterm and term amniotic fluid; 
b) demonstrate its presence in pre- and postnatal serum. 
IV.2. Materials 
Human, bovine and ovine albumin, lactoglobulin A & B, 
transferrin and ceruloplasmin were purchased from Sigma 
Chemical Co (St. Louis, Mo.). Alpha-fetoprotein, alpha 1-
acid glycoprotein, Gc-globulin, beta2-glycoprotein I, 
alpha-HS-glycoprotein, glycoprotein fraction VI and protein 
standard plasma* came from Behringer-Calbiochem. (Cal., USA). 
Sephadex and Sepharose were from Pharmacia Fine Chemicals 
(Uppsala, Sweden). 99.5% pure Tris was purchased from Koch-
Light Laboratories (Colnbrook, U.K.). Dextran-charcoal tab-
lets were provided by Becton & Dickenson (Orangeburg, N.Y.). 
Anti-human-albumin gamma globulin was obtained from Tago 
Industries (Burlingane, Cal.), sheep anti-rabbit gamma glob-
ulin from Welcome (Beckingham, U.K.). 
Preterm amniotic fluid (AF) was obtained for diagnostic 
purposes by amniocentesis at a gestational age of 16-22 
weeks. Term AF was obtained during delivery either per vagi-
nam at the time of rupture of the membranes or during Cae-
sarian section (kindly provided by prof. dr. H.C.S. Wal-
lenburg, department of obstetrics, Erasmus University, Rot-
terdam). 
*The protein standard plasma contained 9e~ ~1: albu~~n 38 
mg, alpha_1-ucid-glyc?protei~ 0. 76 >7:~, -==~~a 1-anti~ry~si:c 2.26 rng, Yiaptoglobul~::c 1.5 ,ng, alph"' 2 "'~--._oglobulEl __ 2 
mq, transferrir. 2.77 r:1g, c 3 c 0.79 mg, c4 0.2 mg, IgG 10.7 
rng, Igl<. 1.63 mg, IgJ'-1 1.01 r.1g (total protein 61.8 r.tg/r.ll). 
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The samples were filtered (paper filter Macherey-Nagel MN 
640), pooled and kept frozen at -70°C until processed. 
Samples showing blood contamination were discarded. 
Cord sera were obtained from term and preterm infants 
(kindly provided by prof. dr. H.C.S. Wallenburg, department 
of obstetrics, Erasmus University, Rotterda~1 and dr. R. 
Straub, Ikazia Hospital, Rotterdam). Urine was collected 
from preterm infants. Fetal blood was sampled without con-
tamination by amniotic fluid or maternal blood during a 
legal abortion. This part of the study was approved by the 
medical ethics committee of the Sophia Children•s Hospital 
(Erasmus University, Rotterdam). From healthy newborns, 
children of 1 to 16 years and adults.,blood samples were 
obtained by venipuncture. In all cases, blood was centri-
fuged at 4°C at 1500 rpm for 20-25 minutes. Serum was col-
lected and kept frozen at -20°C until use._ 
JV.2.1. Amniotic fluid binding protein (AFBP) 
AFBP was isolated from preterm amniotic fluid, as de-
scribed in chapter III. 
IV.3. Methods 
JV.3.1. AFBP charcoal binding assay 
The methodology of the AFBP charcoal binding assay is 
explained in chapter III. 
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IV.3.2. IGF-1/ SM-C radioimmunoassay 
SM values were determined by IGF-I/SM-C radioimmunoassay 
(courtesy of dr. H.J. Guyda, McGill University, i>~lontreal), 
as previously described (Guyda et al., 198lb). The antibody 
to SM-C was obtained through the National Pituitary Agency/ 
National Institute of Arthritis, Metabolism and Digestive 
Diseases (USA). IGF-I was iodinated by the chlorarnine--T 
method and purified by Sephadex chromatography. Results 
are normalized against an ORTHO standard serum pool, ar-
bitrarily assigned a value of l unit/ml. 
IV.3.3. Production of antiserum 
Two mature white rabbits, weighing 4 kg each, were im-
munized. In the primary injection both animals received 
150 vg {protein} of HSGFC purified rnaterial,dissolved in 
250 ~1 of 20 mM Tris-HCl, pH 7.0 1 emulsified in complete 
Freund adjuvant and given subcutaneously at four sites. 
One rabbit showing detectable AFBP-antibodies was rechal-
lenged at intervals of 4-6 weeks with 150-300 ~g (protein) 
HSGFC purified AFBP, emulsified in incomplete Freud adju-
vant. This rabbit was bled from the central ear artery 10 
days after each immunization. After clotting, the blood 
samples were centrifuged at 1500 rpm for 25 minutes at 4°C 
and the sera were collected and stored at -20°C. Immunogel 
electrophoresis of this antiserum showed that it was not 
rnonospecific and displayed two precipitin lines when re-
acted against human amniotic fluid. One of the precipitin 
lines showed a reaction of identity with human albumin. 
Therefore 1 rabbit antiserum (3 ml aliquot) was applied 
to a CN-Br activated Sepharose 4B column (1.6 x 40 ern), to 
which human albumin (Sigma) was coupled according to the 
manufacturer's instructions (Pharmacia Fine Chemicals, Upp-
sala, Sweden) . 
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IV.3.4. Radioimmunoassay of AFBP 
HSGFC purified AFBP (10 ~g protein) was iodinated by a 
modification of the chloramine-T method (Drop et al., 1979). 
The iodination mixture was chrornatographed on a Sephadex 
G-75 column (1 x 25 em) at 4°C with 0.01 M HCl-0.1% BSA as 
eluting buffer. Fractions with highest binding to the anti-
HSA-free rabbit antiserum (Kav 0.1- 0,25) were pooled and 
stored at -20°C until use. HSGFC of purified labeled AFBP 
is shown in fig. IV. 1. , 
IV.3.4.1. Nonequilibrium assay procedure 
Reagents were added to 1 x 7.5 em polyethelene tubes in 
the following order: to 100 ~1 of standard or unknown, di-
luted in 500 vl PBS buffer, was added 100 vl anti-AFBP anti-
serum (dilution 1:500). After incubation at 4°C for 24 hours, 
100 vl 125 I-AFBP, about 20,000 cpm, was added. 24 hours 
later, 100 ~1 of a 1 : 100 dilution of normal rabbit serum 
and 100 ~1 of a 1 : 24 dilution of sheep anti-rabbit anti-
serum (Welcome Laboratories, Beckingham, U.K.) were added. 
Following overnight incubation (! 16 hours), the tubes were 
centrifuged at 3000 rpm for 20 minutes at 4°C. The super-
natants were discarded and the pellets counted in a Searle 
gamma counter (model 1195). 
IV.3.4.2. Equilibrium assay procedure 
To 100 ~1 of standard or unknown, diluted in 500 ~1 PBS 
buffer, were added 100 "l 125 r-AFBP (! 20,000 cpm) and 100 
~1 anti-AFBP antiserum (dilution 1:500). After incubation 
for 72 hours, the reaction was terminated by the addition 
of second antibody and normal rabbit serum as described 
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High speed gel filtration chromatography of 125 r-AFBP, mobile 
60 
min. 
phase Tris-HCl buffer, pH 7.4. AFBP was iodinated by the chloramine-
T method. The iodination mixture was purified by Sephadex G-75 
chromatography (buffer: 0.01 M HCl-0.1% BSA), 
Fig. IV.l.b. 
High speed gel filtration chromatography of 125r-IGF-II (ILAs), 
running conditions as above. IGF-II was iodinated by the chlora-
mine-T method and purified by adsorption to and elution from a 
placenta membrane receptor preparation (Posner et al., 1977). 
ahove. It was determined that, at a final dilution of 
1 : 5000 of antiserum, 35-40% of 125I-AFBP (~ 20,000 cpm, 
as used in the radioimmunoassay) was bound to antibody in 
the absence of added unlabeled AFBP. Without the addition 
of antiserum, 4-6% of 125 I was recovered in the pellet, 
representing a small amount of nonspecific binding of 125I-
AFBP in the assay. 
IV.3.5. Samples 
Amniotic fluid samples and Sephadex G-200 column frac-
tions (see below) were assayed in duplicate at one or more 
concentrations. 
IV.3.6. Gel filtration of serum or plasma under acid conditions 
1 rnl serum or plasma was 
M HCl and kept at 4°C for 6 
acidified with 5 drops of 0.6 
hours. It 
a Sephadex G-200 column (1 x 100 ern), 
was eluted at 
was then applied on 
equilibrated in 0.01 
4°C with 0.01 M HCl M HCl, pH""" 2. The column 
at 0.08 rnl/rnin. The void and inclusion volumes were deter-
mined with dextran blue and Na- 125 r respectively. 2.5-3 ml 
fractions were lyophilized and reconstituted into 0.4 ml 
0.01 M HCl for further analysis. 
IV.3.7. Gel filtration of serum or plasma at neutral pH 
1 ml of serum or plasma was applied on a Sephadex G-200 
column (1 x 100 em), equilibrated in 0.01 M NH 4Hco 3 , pH 7.4. 
The procedure followed the same steps as described above. 
Some of the serum samples were acidified with 5 drops of 
0.6 M HCl, incubated at 4°C for 6 hours and neutralized 
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with 5 drops of 0.6 M NaOH, before chromatography at neutral 
pH. 
IV.3.8. Double immunodiffusion in gel 
Double immunodiffusion in gel was carried out by the 
method of Ouchterlony {1962), with gels prepared from 1.5% 
agar in 0.4 M Tris-barbital buffer, pH 8.8. AgNo 3 staining 
was performed according to the method of Karcher (1980). 
Fig. IV.2. 
Immunoelectrophoresis of undiluted anti-HSA-free antiserum and con-
centrated (lOx) preterm amniotic fluid (upper well) and fetal serum 
(lower well). One precipitin line is visible following silver stai-
ning of the gel. 
IV.4. Results 
IV.4.1. Anti-AFBP antiserum 
The antiserum, obtained after immunization of one rabbit 
with an HSGFC purified AFBP preparation, was not monospecif-
ic but showed a second precipitin line following immunoelec-
trophoresis of preterm amniotic fluid. This contaminating 
protein was immunologically identified as human albumin. 
Therefore, the antiserum was freed of anti-albumin by appli-
cation of the antiserum on an HSA-substituted Sepharose 4B 
column. Immunoelectrophoresis of concentrated preterm amni-
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otic fluid an(: fetal serum resulted in one precipitin 
line (fig. IV.2.). 
IV.4.2. Radioimmunoassay (characteristics) 
Fig. IV.3. shows the displacement of 125 I-AFBP from 
anti-AFBP-antibody by increasing amounts of unlabeled part-
ly purified AFBP during the equilibrium and nonequilibrium 
assay procedure. The competitive dose-response curve of 
Sephadex G-150 purified material (step 3, table III.1.), 
determined by the nonequilibrium assay procedure, was des-
ignated as a standard curve and used in all subsequent 
assays. Results are expressed in ~g equiv./rnl. Dilution 
curves of AF, acid-ethanol extract and Sephadex G-150 and 
HSGFC purified material run parallel to the standard curve 
(fig. IV.4.). Interassay varlation, as determined by assay-
ing the same sample in 14 consecutive assays and expressed 
as the coefficient of variation, was 10%. 
JV.4.3. Hormonal specificiry 
Hormonal Specificity 
A variety of serum proteins listed in table IV.1. was 
tested for cross-reactivity in the AFBP-RIA. No specific 
displacement of 125 r-AFBP by these proteins was observed 
at a concentration of 1 mg/ml. 
JV.4.4. Binding srudies AFBP-RIA 
The bound/free ratio was plotted against the bound 
fractions of dilutions of partially purified AFBP (Sepha-
dex G-150 purified material (step 3, table III.1.}). The 
data suggest the presence of at least two classes of bind-
ing sites of the antibody (fig. IV.S.). 
95 
IV.4.5. Amniotic fluid samples 
AFBP levels in preterm and term AF determined by AFBP-
RIA are given in fig. IV.6 .• The mean+ SEM AFBP level in 
30 preterm AF samples (gestational age of 16-20 weeks) was 
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1-19 equiv/ml 
AFBP Radioimmunoassay. 
Competitive-dose response curve for a partially purified AFBP pre-
paration (step 3, table III.l.}. AFBP content is expressed as \Jg 
equiv. (protein) /ml and plotted against 100 x ~0=~~, where Bo 
125r-AFBP, bound in the absence of added unlabeled AFBP, and B = 
125r-AFBP, bound in the presence of different concentrations of 
unlabeled hormone. 
o-----0 =equilibrium assay procedure;o------o 
assay procedure. 
non-equilibrium 
148 + 18 ~g equiv./ml. In term AF (38-40 weeks of gestation) 
the mean (.:!:_ SEH) value was 72 + 11 ~g equiv./ml (n = 12). 
The difference between t.he mean pre term and term values j s 
statistically significant (p <:.O. OS). IGF-:-I/SM-C values 
(.:!:. SEM) in preterm and term amniotic fluid were uniformly 
very low (mean 0.08 + 0.01 U/ml and 0.08 + 0.02 U/ml re-
spectively; no statistical difference). 
Table IV.1. 
Cross-reactivity {concentration 1 mg/ml) 
Protein 
Lactoglobulin A 
Lactoglobulin B 
B 2 -glycoprotein 
a2-acid-glycoprotein 
Ovalbumin 
a2-HS-glycoprotein 
Gc-globulin 
a- fetoprotein * 
BSA 
HSA 
Transferrin 
Ceruloplasmin 
Glyco-protein fraction IV 
(Behringer) 
Normal standard serum 
(Hoechst) 
!LAs (IGF-II)u 
~o.2 wg/ml 
**25 ng equiv. /ml 
35,000 
35,000 
40,000 
40 1 0 0 0 
43,000 
49,000 
50,000 
64,000 
67,000 
68,000 
75,000 
13,200 
9,400 
B-NS 
Eo-NS X 100% 
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Fig. IV.4. 
Dilution curves of preterm amniotic fluid and partially purified 
AFBP showing parallelism. 
~standard; o---c amniotic fluid;o-·-o ethanol-extract; 
•----•HSGFC purified AFBP. 
B/F 
0.4 
0.3 
0.2 
0. l 
0. l 0.2 0.3 0.4 
pg equiv. bound 
Fig. rv.s. 
Scatchard analysis of the AFBP-RIA standard curve obtained by non-
equilibrium assay procedure, suggesting the presence of at least 
two classes of binding sites of the rabbit antibody. 
JV.4.6. Urine samples 
In 3 urine samples of preterrn born infants (gestational 
age 32-34 weeks), AFBP values were 0.08, 0.08 and 0.1 ug 
equi v ./rnl. 
IV. 4. 7. Gel filtration of amniotic fluid and serum 
Preterrn AF was chrornatographed on Sephadex G-150 columns, 
at both pH~2 and 7.4. AFBP-RIA activity was eluted at K 
av 
0.45-0.6 {fig. IV.7.), similar to AFBP-CBA activity {cf. 
fig. III.2.). 
When serum was chromatographed on Sephadex G-200 at pH 
2.2, AFBP-RIA activity was eluted in one peak at Kav 0.6. 
Highest activity was found in fetal serum (gestational age 
of 20-22 weeks) (fig. IV.S.a.)-, lowest in serum from 
adults (male or female) (fig. IV.8.c., d.). It was possible 
to demonstrate AFBP-RIA activity in serum of GH>-de.ficient 
patients (fig. IV.S.e.). No activity was present in rat, 
rabbit, porcine or bovine serum (data not shown}. 
The effect of pH and prior acidification (see Methods 
for details) on the elution profile of fetal and cord se-
rum is shown in fig. IV.9. and fig. IV.lO .. When fetal se-
rum was chromatographed at neutral pH, the predominant 
form of SM binding activity was found at Kav 0.5-0.75, 
corresponding with a molecular weight range of 30-60,000 
(fig. IV.9.a.). IGF-I/SM-C RIA activity was found in the 
corresponding fractions (fig. IV.9.c.). Under acid condi-
tions, however, SM binding activity, as determined by 
AFBP-CBA activity, was found in the large molecular weight 
range at Kav O.l-0.4 (fig. IV.9.a.). AFBP-RIA activity 
was found only at Kav 0.5-0.75, irrespective of pH or 
prior-acidification of both fetal and cord blood. Fractions 
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were generally higher when serum had peen acidified. 
When fetal serum, previously acid-treated as outlined 
above, was chromatographed at neutral pH in the presence 
of labeled SM (IGF-II), radioactivity was still eluted at 
Kav 0.6 only (data not shown). 
Large and small molecular weight SM binding proteins 
were present in cord blood (fig. IV.10.a.b.c.). At neutral 
pH
1
IGF-I/SM-C predominantly eluted at Kav 0.15-0.4, cor-
responding with a molecular weight range of 150-200,000. 
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ted preterm AF samples (gestation of 16-22 weeks) and 12 term AF 
samples. SM values (e) were determined by IGF-I/SM-C RIA (ordinate, 
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Sephadex G-150 chromatography (column size 1 x 100 em) of preterm 
amniotic fluid (fig. IV.7,a.) and ethanol-extract (fig. IV.7.b.}. 
Buffer: 0.01 M HCl, pH"""-' 2. 1 ml fractions were lyophilized and 
reconstituted into 0.2 ml assay buffer. AFBP-RIA activity was re-
covered only in fractions at Kav 0.45-0.6, similar to AFBP-CBA 
activity (cf. fig. III.2.) and similar to the elution volume of 
labeled AFBP. The elution profile of AF chromatographed at neutral 
pH {Tris-HCl,.pH 7.4) was identical (data not shown}. 
/'\.. "" OD280 ; I = AFBP-RIA activity. 
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Sephadex G-200 chromatography (column size 1 x 100 em} of 1 ml 
serum. Buffer: 0.01 M HC1 1 pH~ 2. 1 ml fractions were lyophilized 
and reconstituted into 0.2 ml assay buffer. 
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a} fetal (~ 20 weeks of gestation}; b) cord (term}; c) adult 
(female}; d) adult (male}; e) patient with GH deficiency (male, 
7 yrs.}. 
IV .5. Discussion 
In this chapter,the development of a specific radioim-
munoassay for AFBP is described. The antiserum was prepared 
by injection of HSGFC purified AFBP into two rabbits. Only 
one rabbit responded with an increase of antibody titer. 
The antiserum was cleared of anti-albumin antibodies by 
application of the antiserum over an HSA-substituted Sepha-
rose 4B column. That the antibody is directed against AFBP 
is suggested by its binding to chrornat0graphically purified 
rl25-AFBP. AFBP-RIA activity was demonstrated in polyacryl-
amide disc-gel fractions showing AFBP-CBA activity (see 
fig. III.4.). The protein isolated from these fractions 
stained as a single band, following analytical polyacryl-
amide gel electrophoresis {see fig. III.6.). Monospeci-
ficity is suggested by the lack of cross-reactivity of a 
limited number of proteins tested (table IV.l.) and by the 
result of immunoelectrophoresis of concentrated preterm 
amniotic fluid and fetal serum in the presence of antise-
rum (fig. IV.2.). The sensitivity of the assay was improv-
ed by adoption of the nonequilibriurn procedure, as shown 
in fig. IV.3 .. 
SM bioactivity has been demonstrated in amniotic fluid 
·(Anderson et al., 1974; Bala et al., 1976 1 1978; Hill and 
Milner, 1981). Generally values were very low, slightly 
higher at term than in early pregnancy {Bala, 1978). 
It was previously reported that no small molecular weight 
insulin-like activity (ILAs) was detectable by placenta 
membrane radioreceptorassay in {pre)term AF, even under 
rigorous protein dissociating conditions, such as acid-
ethanol extraction and chromatography in 8 M urea (Drop et 
al., 1979). Our present results indicate that IGF-I/SM-C 
radioimmunoassay activity is barely detectable in preterm 
and term AF. 
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Sephadex G-200 chromatography (column size 1 x 100 em) of fetal 
serum. 
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m1 serum was acidified with 5 
hours and chroma to graphed in 
m1 serum was chromatographed 
m1 serum was acidified with 5 
drops of 0.6 M HCl, kept at 
0. 0 1 l1 HCl, pH 2.2. 
in 0. 0 1 M NH 4Hco 3 , pH 7. 4. 
drops of 0.6 M HCl, kept at 
4°C 
4°C 
for 6 hours, neutralized with 5 drops of 0.6 M NaOH and chromate-
graphed in 0.01 M NH 4Hco 3 , pH 7.4. 
The fractions were lyophilized and reconstituted with assay buffer 
into 1/5 of the original volume. 
a. The fractions were measured by AFBP-CBA. At neutral pH the pre-
dominant activity is found at Kav 0.45-0.7. Following acidifi-
cation of the serum, some of the SM binding is retained in the 
large molecular weight range. 
b. The fractions were measured by AFBP-RIA. There is only assayable 
activity at the elution volume of labeled AFBP (Kav 0.5-0.7). 
The AFBP-RIA activity in the fractions of acidified serum appears 
to be higher than in the fractions of serum chromatographed at 
neutral pH. 
c. IGF-I/SM-C content of the fractions was measured by RIA. At neu-
tral pH predominant elution of activity occurred at Kav 0.45-0.7. 
After acidification, unbound Sl-1 is found at Kav 0. 8. 
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Fig. IV.10. 
Sephadex G-200 chromatography (column size 1 x 100 em) of cord serum. 
~ ml serum was acidified with 5 drops of 0.6 M HCl, kept at 4°C 
for 6 hours and chromatographed in 0.01 M HCl, pH 2.2, 
[J ml serum was chromatographed in 0.01 M NH 4Hco 3 , pH 7.4. 
a. The fractions were measured by AFBP-CBA. At neutral pH activity 
is found not only at Kav 0.45-0.7, but also at Kav 0.2-0.4. 
Following acidification; the activity was markedly increased. 
b. The fractions were measured by AFBP-RIA. Findings similar to 
fig. IV.9.b. 
c. The fractions were measured by IGF-I/SM-C RIA. At neutral pH 
predominant elution of activity at Kav 0.15-0.4. After acidifi-
cation, activity shifts to Kav 0.6-0.8, representing unbound SM. 
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Chochinov•s suggestion, that SM binding activity in AF 
is of fetal origin (Chochinov et al., 1976)
1 
may well be 
correct since AFBP-RIA activity was found in urine of pre-
term infants. 
The chromatographic profile of preterm amniotic fluid 
and pre- and postnatal serum is identical, pointing to a 
protein (or proteins) with an apparent molecular weight of 
~ 40,000. No RIA activity could be demonstrated in the 
large molecular weight range at neutral pH or under acid 
conditions. As shown in fig. IV.8., 9. and 10., it is evi-
dent that AFBP-RIA activity is present in pre- and postna-
tal serum. Activity appears to be highest in fetal serum, 
lowest in adult serum. 
We confirm the observation by D'Ercole (1980) that at 
neutral pH the elution patterns of IGF-I/SM-C in fetal and 
cord serum differ. In fetal serum of infants of less than 
27 weeks of gestation, IGF-I/SM-C elutes at an apparent 
molecular weight of 40,000 (fig. IV.9.c.), whereas in cord 
serum the predominant elution occurs at a molecular weight 
of 150-200,000 (fig. IV.10.c.). SM binding activity, as 
determined by the AFBP-CBA, is found in the corresponding 
fractions (fig. IV.9.a., lO.a.). When fetal serum, however, 
is acidified and chromatographed at either acid or neutral 
pH, SM binding activity is also discovered in the large 
molecular weight range. By acidification of serum, SM is 
separated from its binding proteins, and the binding sites 
of the binding proteins are increased (Daughaday et al., 
1980). In fetal serum, large molecular weight binding pro-
teins may be present. Because of the low content of IGF-I/ 
SM-C in fetal serum, they may escape detection when IGF-I/ 
SM-C is measured in the individual fractions (fig. IV.9.c.). 
Alternatively and more likely, the AFBP-CBA activity found 
at Kav 0.1-0.4 may represent the elution of small molecular 
weight binding proteins, nonspecifically bound to large 
molecules. 
us 
Sara measured SM activity in human serum by radiore-
ceptorassay, utilizing human fetal brain plasma membrane 
as matrix (Sara et al., 1981). Levels in fetal serum were 
found to be increased, not only compared with adult values, 
but also with SM values measured by radioimmunoassay. On 
the basis of this discrepancy between SM values measured in 
fetal serum by RRA and RIArSara postulated that in the hu-
man fetus an embryonic form of SM exists. At the end of 
the first half of gestation., this embryonic SM is present 
at high concentrations. During the seconO half of gesta-
tion1the values gradually fall as adult forms of SM begin 
being produced. However, in this study native serum v1as 
tested and fetal serum was not subjected to another RRA. 
This chapter describes that substantial quantities of SM 
binding activity in fetal serum have been demonstrated. 
Therefore, the discrepancy between RRA and RIA SM values 
in fetal serum can be fully explained by interference of 
SM binding proteins, in the RRA, such as AFBP, leading to 
spuriously high values. 
The next step in the investigation of the biological 
significance of AFBP, now shown to be present in pre- and 
postnatal serum, was to explore its relationship with small 
molecular weight SM in pre- and postnatal serum and in se-
rum of patients with various growth disorders. In chapter 
v, results of some initial studies are presented. 
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CHAPTER V 
AFBP DETERMINATION IN NATIVE SERUM OR PLASMA 
V.I. Introduction 
It has been well established that small molecular weight 
SM circulates in plasma,rnainly bound to macromolecular car-
rier or binding proteins (a.o. Zapf et al., 1975; Hintz 
and Liu, 1977; Furlanetto, 1980; Daughaday et al., 1982a). 
At least two different binding proteins with high affin.i..ty 
and specificity for SM exist. The major one (150-200,000 
MW) consists of two protein subunits, one of which is 
acid-stable and contains the structural determinants nec-
essary for binding SM, while the other is acid-labile 
(Furlanetto, 1980). The acid-stable subunit appears to be 
under GH control (a.o. Zap£ et al., 1978; Copeland et al., 
1980; White et al., 1981; Schalch et al., 1982). In addi-
tion, plasma contains an unsaturated, acid-stable form of an 
SM binding protein with a 35-50,000 MW (Hintz et al., 1981). 
Thusfar1 plasma SM binding activity has been determined by 
incubation of serum fractions with labeled SM and separa-
tion of unbound from bound SM with dextran-charcoal (Moses 
et al., 1979; Zapf et al., 1980; Hintz et al., 1981; Daug-
haday et al., l982a). 
The biological significance of the serum concentration 
of this SMBP is largely unknown. Evidence reveals that 
under physiological and various pathological conditions 
the serum SM binding activity differs greatly. Levels of 
the unsaturated SMBP (~ 40-50,000 MW) are elevated in se-
rum of patients with GH deficiency and decline during GH 
treatment (Hintz et al., 1981). Increased values have been 
lll 
found in cord serum and in serum of uremic patients (Borsi 
et al., 1981; Goldberg et al., 1982). The SM binding pro-
teins are probably generated in the liver (Binoux et al., 
19 82) • 
The availability of a specific RIA for a± 40,000 MW SM 
binding protein1 isolated from preterm amniotic fluid 1 allow-
ed an initial exploration of the relationship between AFBP 
and small molecular weight SM in pre- and postnatal serum 
and of its homology with known serum SM binding proteins. 
V .2. Materials and methods 
V.2.1. Samples 
Human fetal and cord blood was obtained as outlined in 
chapter IV. From newborns, children and adults, blood sam-
ples were obtained by venipuncture between 9 and 11 am. In 
all cases, blood was centrifuged at 4°C at 1500 rpm for 20-
25 minutes. Serum or plasma was collected and kept frozen 
at -20°C until use. 
V.2.2. AFBP-RIA 
AFBP was assayed in native serum or plasma (dilution 
range 1:2 I 1:600) by radioimmunoassay as outlined in chap-
ter IV, with the following mOdification: to the tubes con-
taining the standard series (dilutions of Sephadex G-150 
purified acid-ethanol extract from preterrn amniotic fluid 
(step 3, table III .1.)) , 100 111 of a 1% solution of bovine 
serum was added. All serum values are the mean of the two 
highest dilutions fitting the standard curve. It was es-
tablished that AFBP-RIA values of native serum and plasma 
give similar results. 
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V.2.3. SM determinations 
Total immunoreactive SM was determined by RIA (Bala and 
Bhaumick, 1979). IGF-I/SM-C was measured by RIA (Guyda et 
al., 1981), and IGF-II was measured by RRA {Posner et al., 
1977). Results are expressed in Ortho standard serum units 
per rnl. 
V.2.4. Conditions studied 
The followin9 conditions were studied: 
V.2.4.a. Diurnal variation 
Plasma samples were obtained from 8 adult volunteers 
(4 male, 4 female; age range of 28-42 years), at 0800-
0900 h, 1300-1400 h and 2200-2300 h on one day. In addi-
tion, from a 12.5-year old girl (after the recent onset of 
insulin-dje.pendent diabetes mellitus) and from a 10-year 
old girl with hypopituitarism, plasma samples obtained 
throughout a 24-hour period were assayed. Glucose, growth 
hormone and cor-tisol determinations were performed accord-
ing to established methods. 
V.2.4.b. Age dependence 
AFBP values v..1ere measured in fetal serum (estimated 
gestation of 18-22 weeks), cord serum (32-40 weeks of ges-
tation) and in serum or plasma from children (boys and 
girls) of 1-17 years of age and healthy adults (hospital 
and laboratory personnel) . The children had been referred 
to the pediatric outpatient clinic of the Sophia Chil-
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dren•s Hospital, Rotterdam, for minor illnesses. Patients 
with endocrine disorders and liver/renal failure were ex-
cluded (see below). 
V.2.4.c. GH dependence 
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a. From 14 patients with GH deficiency, age range of 
0.5-15 years, plasma was obtained before GH treatment 
was initiated. The diagnosis of GH deficiency was based 
on short stature (standard deviation score corrected 
for height (SDSh) less than -2.3), delayed bone matu-
ration and an insufficient GH response during at least 
two stimulatory tests, while the patient was euthyroid. 
In 3 patients on GH treatment (5 mg Nanormon R i.m. 
twice weekly for 9-27 monthst the effect of a single 
GH injection was investigated. 
b. HGH was administered to 6 patients with GH deficiency 
{3 male, 3 female, age: 8-16 years). All subjects conformed 
to the criteria for GH deficiency, established in Canada. 
The peak serum GH level after insulin-induced hypogly-
cemia and arginine infusion was less than 5 ng/rnl. Fast-
ing plasma samples were obtained at 0, 4, 24 and 72 
hours after a single injection of HGH and after 1 and 6 
months of chronic HGH therapy. 
have been reported previously 
Results of this study 
b (Guyda et al., 1981 ) . 
c. From a patient with Laron dwarfism (age: 22 years)
1 
blood was obtained. This patient has been described in 
detail (Van den Brande et al., 1974b). 
d. Blood was obtained from a girl (age~ 14 years) with 
growth acceleration and biochemical evidence of acromeg-
aly. 
V.2.4.d. Sex-steroid dependence 
From adolescents with tall stature (15 girls and 9 boys; 
diagnosis: constitutional tall stature in 22 patients, Mar-
fan Syndrome in 2 patients; age: 10-15 years )1 plasma sam-
ples were obtained before and during treatment (2-8 months) 
with high doses of estrogens in girls (ethynylestradiol 200 
~g/d p.o.) and androgens in boys (Sustanon R, Organon, 
250 mg i.m. once weekly). Details about this study will be 
reported on separately (Hokken-Koelega et al., in prepara-
tion). SM-C and AFBP levels were measured in the same 
samples. 
V.2.4.e. Other physiological and pathological conditions 
From 6 patients (4 boys, 2 girls; age: 5-18 years) with 
end stage renal failure and on hemodialysis treatment, se-
rum was obtained prior to a dialysis session. Serum (l ml) 
of 3 patients was chromatograpned on a l x 100 em Sephadex 
G-200 column at neutral pH. From healthy pregnant women 
attending the obstetric outpatient clinic (head prof. dr. 
H.S.C. Wallenburg) of the University Hospital Dijkzigt, 
Rotterdam, blood was obtained at 36 weeks of gestation. 
V.2.4f. Other species 
Blood was obtained from nonimmunized rats, rabbits, 
orang-outangs (mothers and children, age: 7-18 months) and 
an elephant (courtesy of dr. M. Frankenhuis V.D., Blijdorp 
Zoo, Rotterdam). Bovine and porcine blood was obtained 
from a local slaughterhouse. 
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V.2.4.g. In vitro studies 
The supernatant of placenta cell explants, obtained 
from a preterm placenta (gestation of 17~ weeks) and from 
a term placenta (courtesy of Wei Lai M.Sc., McGill Univer-
sity, Montreal), was assayed for AFBP-RIA activity, fol-
lowing 1-5 days of incubation in a culture medium contain-
ing 10% fetal calf serum. The supernatant of a hepatoma 
cell line (PLC/PRF/5; MacNab et al., 1976) was similarly 
assayed (courtesy of dr. H.K. Yap, department of internal 
medicine, Radboud Ziekenhuis, Nijmegen}. 
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AFBP-RIA activity of dilutions of native fetal serum samples (a-e) 
as compared to the standard series (std.) (dilutions of Sephadex 
G-150 purified acid-ethanol extract of preterm amniotic fluid, step 
3, table III.1J, to which a 1% solution of bovine serum has been 
added. 
V.2.5. Statistical analysis 
Where appropriate~ results are expressed as means± 
standard error of the mean; the data were analysed on a 
Hewlett packard desk top computer type 9825B. Significance 
was determined by the Krustal-Wallis test, as described by 
Conover (1980). 
V .3. Results 
V.3.1. AFBP-RIA of native serumjpiasma 
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Fig. V.l.b. 
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c 
a 
dilution 
b 
std. 
AFBP-RIA activity of dilutions of fetal serum samples (untreated a, 
b, c -- ; acid-treated a', b', c' ----), as compared to the stan-
dard series (std). 
Acid treatment of serum results in a slight shift to the left of 
the dilution curve. 
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Serum dilutions in a range of 1:20 I 1:600 generally 
showed parallelism with the standard curve (fig. V.1.a.). 
In serum diluted less than 1:201 the difference between the 
mean value and the two values, from which the mean was cal-
culate~ averaged 38% of the mean value (range 10-65%i n 
19). Prior acidification of the serum or plasma sample 
with 0.6 M HCl for 4-6 hours at 4°C, followed by neutrali-
zation with 0.6 M NaOH, resulted in a slight shift of the 
dilution curve "to the left" (fig. V.l.b.). The calculated 
AFBP values were generally higher than those in untreated 
serum or plasma. 
AFBP 
pg equi,Yml 
1.2 
0.8 
0.4 
10 
Fig. V.2. 
12 14 16 18 20 22 24 
time (hro.) 
Diurnal variation of AFBP plasma values in 8 adult volunteers {4 
males, 4 females}. The mean mOrning value (.:!:_ SEM} was 0. 7 + 0.1 \l9 
equiv./ml and differed significantly from the mean afternoon 0.5 2: 
0.1 \lg equiv./ml and midnight value (0.3 2: 0.1 \lg equiv./ml) at a p 
level of 0.05 and 0.005 respectively. 
( "female; 11 male; mean; ----- SEM} . 
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Table V. 1. 
AFBP, GH, cortisol and glucose were determined throughout a 24-
hour period in a 10-year old girl ( I ) with idiopathic GH defi-
ciency and in a 12.5-year old girl ( IIlwith recent diabetes mel-
lit us and treated with i.v. crystalline insulin. 
Pat. I (~; age: 10 yrs.) Dx: GH deficiency 
t AFBP GH cortisol glucose 
hrs. ,g equiv. /ml 1 U/L ).lmOl/L rnmol/L 
08.00 2.0 0.5 
11.00 0.5 3 
14.00 0.4 4 
16.00 0.3 2 0. 15 
20.00 0.5 2 
22.00 0.6 0.5 0.04 
01.00 0.6 3 
0 3. 00 1.7 3.5 0.23 
05.00 1.5 5 
08.00 1.9 0. 30 
Pat. II (~; age: 12.5 yrs.) Ox: diabetes mellitus 
type I. Rx: crystalline, insulin i.v. 
08.45 2.0 4 0. 36 16.4 
09.45 1.6 2 0.2 15.9 
11. 30 0.6 15 0.08 13.8 
14.00 0.7 5 0. 16 13.5 
16. 30 0.7 12 0. 12 13.3 
19. 30 10.0 
2 3. 00 1.4 3 0.04 13.2 
03.00 1.3 4 0.04 
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FS cs 
Fig. V.J. 
0-1 
yrs. 
2-7 
yrs. 
8-ll 
yrs. 
12-17 
Y"· 
AS preg GHD 
36 wks. 
LTD' RF 0-0 
GHt ** 
AFBP concentrations plotted on a semi-logarithmic scale in native 
serum or plasma. 
FS =fetal serum (18-22 weeks of gestation); CS =cord serum (32-
40 weeks of gestation};children of 0-1, 2-7, 8-ll, 12-17 years with 
non-endocrine illnesses. 
AS = adult serum; preg =healthy pregnant women at 36 weeks of ges-
tation; GHD = GH deficiency; RF =renal failure; LTD= Laron type 
dwarfism; GH0 = GH excess; 0-0 = Orang-Outang (.Amother; A child); 
6=other animals (see text). •= female; •= male. f =mean ± SEM. 
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FS 
Fig. V.4. 
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IGF-I/SM-C concentrations in native plasma (determined by H.J. Guyda, 
McGill University, Montreal). 
The values of healthy children of 0-18 years were obtained by H.J. 
Guyda, McGill University, Montreal (unpublished observations). For 
an explanation of abbreviations see legend figure V. 3. 
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V.3.2. Conditions studied 
V.3.2.a. Diurnal variation 
Plasma AFBP values in 8 adults were highest early in 
the morning, declining during the day {fig. V.2.). A pa-
tient with recent diabetes mellitus and with intact GH 
and cortisol secretion, as well as a girl with GH defi-
ciency and with a normal cortisol diurnal rhythm showed 
the same pattern (table V.l.). 
V.3.2.b. Age dependence 
The mean (~ SEM) AFBP value in fetal serum was 36.7 + 
15.7 ~g equiv./ml (n = 17). In cord serum this value was 
2.8..:!: 0 .. 4 f.lg equiv./rnl (n = 19). The difference is statis-
tically not significant. In postnatal serum, the AFBP 
value gradually fell to adult levels of 0.6 ~ 0.07 "g 
equiv./rnl (n = 19). There was no difference between samples 
from males and females. IGF-I/SM-C values, determined in 
the same samples, were hardly detectable in fetal serum 
(mean 0.07 + 0.01 U/ml (n = 6)). In cord serum the mean 
value was 0.22 + 0.04 U/ml (n = 12). In the age range of 
0-18 years 1 there was a gradual rise of IGF-I/SM-C values. 
In adults SM-C values were generally lower than in puber-
tal individuals (fig. V.3., 4.). 
V.3.2.c. GH dependence 
The mean AFBP value in serum from children with GH de-
ficiency (mean age 11.7 years, range 6.5-17 years; n = 23) 
was 2.0 + 0.2 ~g equiv./rnl, significantly higher than 
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ug equiv ./ml SM U/ml 31 911 yrs. r 12 
1 I ~I ~I II ~I _1 I d ~~ 
3
1 
I 9 15yrs. r 1.2 
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:11 ~ I d • ~~ I & I ~ '"~ 1 :· 
:11_1 J ~ I_ "~J 
:11wwl8fb 
:1~1 ~~~ 
0 4 24 72 hrs. 6 mo. 
Fig. V.S. 
The effect of GH treatment on SM and AFBP serum values in 6 patients 
at 4, 24 and 72 hours after a single injection of GH and after l and 
6 months of continuous GH treatment. 
AFBP values are indicated on the ordinate, left panel. SM values 
are indicated on the ordinate, right panel: 
t:::kl total immunoreactive SM, determined by RIA (Bala and Bhaumick, 
19 79) . 
c=J IGF-I/SM-C, determined by RIA (Guyda et al., 1981). 
~ IGF-II, determined by RRA (Posner et al., 1977). 
II AFBP, determined by RIA. 
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that found in the control groups in the age range of 7-ll 
years (P<.0.05) and 11-17 years (P-.::::.0.05). As expected
1 
SM 
values were markedly decreased (mean 0.21 = 0.06 U/ml). 
In 3 patients with GHD and on GH treatment for 9-24 
months, the effect of a single i.m. injection of GH iS 
given in table V.2 .. In patient IV, a substantial rise of 
SH was found 20 hours after the GH injection. AFBP values 
showed a decrease. In the other two patients, no substantial 
rise of SM occurred following a single GH injection. AFBP 
morning values were increased. In 6 children with GH de-
ficiency, AFBP and SH values were measured before and 4, 24 
and 72 nours after one injection of GH (5 U) and then af-
ter 1 and 6 months of chronic GH treatment (dosage: 0.1 
Table v. 2. 
The effect of a single i.m. injection of GH (5 rng, Nanormon ~ in 
3 patients with GH deficiency on chronic GH treatment for 9-24 months 
day time AFBP IGF-I/SM-C GH Rx: GH (Nanormon R) 
hrs. ,g equiv./ml or tho U/ml lU/L 5 rng i.m. 
Pat. III (,f; age: 15 yrs.; Tanner P1G1) 
17.00 0.40 0. 11 
17.30 X 
2 0 8. 30 1.9 0. 17 0.5 
16.00 0. 8 0. 15 0. 5 
Pat. IV (,J; age: 14 yrs.; Tanner P1G1) 
1 17.00 0. 6 0. 3 2 
20.00 X 
2 08.00 0. 5 0.63 32 
12.00 0.5 0.62 3 
14.00 0. 5 
16.00 0. 4 1.0 1 
20.00 0.2 0.57 0. 5 
Pat. v (~; age: 1,5 yrs,) 
18.00 0. 7 0.23 0. 5 
18.30 X 
2 09.00 3. 0 0. 14 1 
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U/ky - 3x/week) (data taken from Dean et al., 1982). The 
SM response to GH varied considerably, and in these 6 pa-
tients no correlation between AFBP and SM values was 
found. In tfte adult with Laron dwarfism,the SM-C value was 
very low whereas the AFBP value was in the upper adult 
range. In the 14-year old girl with GH excess, the SM-C 
value was markedly elevated and AFBP in the normal range 
for age. 
t. AFBP 
pg equiv./ml 
0 u• 6 + 1.0 
0 
0.5 
• • • 0 
0 
0,5. 0 0 0 
• 
1.0 
D 
• 0 
0.5 
Fig. V.6. 
• 
• 
• 
• 
0.5 
• 
1.0 
D 
• 
, IGF-1/SM-C 
+u U/ml 
The effect of sex-steroid treatment on SM and AFBP values in adoles-
cents with tall stature. 
On the abscissa the change of SM serum values during sox-steroid 
treatment is plotted. The ASM is defined as the SM plasma concen-
tration at 2-4 months (e=~; •""cfl or 5-8 months (0=9; c=r1) 
minus the value obtained at the beginning of treatment. Similarly, 
on the ordinate the change of AFBP values in the same serum samples 
is indicated. 
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V.3.2.d. Sex-steroid dependence 
In the adolescents with tall stature, treated with su-
praphysiological doses of sex-steroids, the change of SM 
values was highly variable (fig. V.6.). In the girls ones-
trogen treatment, AFBP values showed an increase whereas in 
the boys, treated with androgens, a slight decrease was noted. 
V.3.2.e. Other physiological and pathological conditions 
In 6 children with end stage renal failure and on hemo-
dialysis treatment, the mean serum AFBP value was 1.6 + 
0.3 ~g equiv./ml (fig. V.3.). Of 3 patients, 1 ml of serum 
was chrornatographed on a 1 x 100 ern Sephadex G-200 column 
at pH 7.4, as described in chapter IV. AFBP-RIA activity 
was measured in the individual fractions. Peak activity was 
found only at Kav 0.55-0.75, and the calculated total AFBP 
content agreed with whole serum values (data not shown). 
In serum of pregnant women (36 weeks of gestation), AFBP 
and IGF-I/SM-C values were elevated: AFBP: mean 2.8 + 
0.3 U/l (n = 12), IGF-I/SM-C: mean 2.2 + 0.3 U/l (n 4) 
(fig. V.4.). 
V.3.2.f Other species 
In undiluted serum of rats, rabbits and one elephant as 
well as in bovine and porcine serum,AFBP-RIA activity was 
at or below the limit of detection (fig. V.3.). However, 
in serum of 3 orang-outang mothers and their 3 children 
(age: 7-18 months )
1 
AFBP values were readily detectable. 
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V.3.2.g. In vitro studies 
No active AFBP production could be demonstrated in cell 
cultures of preterm and term placentae. In supernatant of 
a hepatoma cell line in culture1 irr~unoreactive AFBP was 
readily detectable: 1.3 ~g equiv./ml. The SM-RIA activity 
was below the limit of detection. 
V.4. Discussion 
As AFBP was detectable in fractions of pre- and postna-
tal serum following Sephadex G-200 chromatoqraphy (chapter 
IV), a simple and yet reliable method for quantitation of 
serum AFBP was desirable. The dilution curve of native se-
rum, at dilutions of 1:20 and up,ran parallel to the dilu-
tion curve of standard series to which 100 ~1 of a 1% so-
lution of bovine serum had been added. In interpreting the 
results of AFBP determinations in native serum at low di-
lutions1 one has to take into account the sensitivity limi-
tations of the radioimmunoassay as a result of a final di-
lution of the antiserum (1:5000) and the low concentration 
of AFBP in terms of protein in postnatal serum (see chap-
ter IV). Still, native serum content or plasma values con-
curred with the sum of the individual fractions, following 
Sephadex G-200 chromatography (data not shown). 
The AFBP serum concentration appears to be influenced 
by several factors. First of all, AFBP values vary during 
the day, as illustrated in fig. V.2., suggesting the pres-
ence of a circadian rhythm sensitive regulatory mechanism, 
operative for pituitary hormones. A practical consequence 
is that comparison of serum concentrations would serve no 
useful purpose unless the time of sampling is known. IGF-I/ 
SM-C values were not measured in these samples, but a de-
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cline of serum SN-C concentrations after the onset of sleep 
has been reported (Minuto et al., 1981). 
Secondly, with the increase of age, AFBP values in pre-
and postnatal serum show a gradual decline (fig. V.3.). The 
opposite holds true for IGF-.I/SH-C values (fig. V. 4.), as 
has been reported by various authors (a.o. Furlanetto, 1980; 
Rosenfeld et al., 1981; Guyda et al., 1981). 
Thirdly, the results of sex-steroid treatment of adoles-
cents with tall stature suggest that AFBP values increase 
during estrogen treatment and decline during androgen treat-
ment, a phenomenon ltlell-known for several plasma proteins, 
such as sex-hormone binding globulin and ceruloplasmin 
(Bergink et al. 1 1976; Drop et al. 1 1981). The IGF-I/SM-C 
response to sex-steroid treatment is highly variable (fig. 
V. 6.) .. 
Finally 1 AFBP values are significantly higher in patients 
with GH deficiency than in age-matched controls. Prelimi-
nary studies indicate that during GH treatment AFBP concen-
trations decline whenever SM values rise (fig. v.s., table 
V.2.). Hintz described a similar paradoxical correlation 
between a nonsaturated, acid-stable SM binding protein with 
an apparent molecular weight of 40,000 and SM-C values be-
fore and after GH treatment of GH-deficient patients (Hintz 
et al. 1 1981). This SH binding protein has also been demon-
strated in cord serum (Borsi et al., 1982). 
By stimulating the production of SM itself and possibly 
of carrier proteins as well, GH is undoubtedly the single 
most important hormonal regulator of the SH concentration 
in serum. In addition, age, sexual differences, pubertal 
stage and particularly the nutritional status are all known 
to influence the SM-C concentration. The exact mechanism 1 
by which these factors exert their influence on SM-C se-
rum concentrations/ is at present unknown and may well 
differ from the one applj_cable to AFBP. Therefore, it should 
12 8 
not be surprising that no statistically significant corre-
lation was found between AFBP and IGF-I/SM-C values, meas-
ured in the same samples of pre- and postnatal serum. 
In serum of pregnant women (36 weeks of gestation), both 
IGF-I/Sril-C and AFBP values were elevated as compared to 
those in adult controls. This, again, points to factors 
other than GH, capable of influencing SM and AFBP serum 
values (Herimee et al., 1982b). In serum of uremic patients 
on hemodialysis, SM values were not measured, but decreased 
IGF-I/SM-C and increased IGF-II values have been reported 
by several authors (a.o. Schiffrin et al., 1978; Goldberg 
et al., 1982). Goldberg found increased concentrations of 
a 50,000 MW SM binding serum component. This fully agrees 
with our results, indicating AFBP values to be higher than 
those of age-matched controls, measured both in native se-
rum and by Sephadex G-200 chromatography. 
No active AFBP production could be demonstrated in cell 
cultures from preterm and term placentae. The liver is 
most likely the main site of production of SM binding pro-
teins (Binoux et al., 1982). In supernatant of a hepatoma 
cell line in culture, immunoreactive AFBP was readily de-
tectable. Moses reported on a human hepatoma cell line, 
HEP G2, secreting large quantities of a specific IGF car-
rier protein into serum-free medium. Similar to AFBP, this 
acid-stable protein has a molecular size of 30,000-50,000. 
It contains no glycoprotein moiety (Moses et al., 1983). 
The immunoreactivity of AFBP appears to be species-specific 
since, of the animal sera tested, only serum of the orang-
outang reacted (fig. V.3.). We conclude that AFBP, a heat-
and acid-stable SM binding protein, originally isolated 
from preterm amniotic fluid 1 shows a striking likeness to 
an unsaturated SMBP in human serum, as described by Hintz 
( 19 81) . 
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
This thesis study was undertaken in order to investi-
gate the nature and biological behavior of a somatornedin 
binding protein, identified in preterrn amniotic fluid (AF). 
Somatomedin (SM) is the generic designation applied to 
a family of serum peptide growth factors which are growth 
hormone dependent, stimulate incorporation of sulphate 
into cartilage, have insulin-like actions on nonskeletal 
tissues and increase mitosis in a wide variety of cultured 
cells. Thusfar two peptides have been fully characterized: 
insulin-like growth factor I (IGF-I), shown to be identi-
cal to sornatomedin-C, and insulin-like growth factor II 
(IGF-II). IGF-I and IGF-II have a 62% aminoacid sequence 
identity and are 38-48% homologous with the A and B domains 
of human pro-insulin. 
As outlined in chapter I, there are various indications 
that SM is involved in the humoral regulation of fetal 
growth. However, many questions as to its identity in fetal 
serum, its origin and mode of action remain unresoived. 
Growth hormone, prolactin, placental lactogen, insulin, glu-
cagon and the nutritional status may all influence the regu-
lation of SM during the fetal period. 
SM circulates in plasma, bound to macromolecular weight 
carrier or binding proteins. In postnatal plasma,at least 
two forms have been recognized (150-200,000 and 40-50,000 
MW). The precise function of these binding proteins is un-
clear. In addition to being carrier proteins, they may 
play an important role in the regulation of the biological 
effects of circulating SM. 
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In chapter II 1 the partial purification and characteriza-
tion of an acid-stable protein with an isoelectric point of 
4.7 and a presumed molecular weight of 35-40,000 are de-
scribed. Furthermore, this protein, termed amniotic fluid 
binding protein (AFBP) , is shown to specifically bind la-
beled Sl:'-1 (IGF-II) and inhibit the insulin- and sornatomedin-
like effects of IGF-II in various in vitro bioassays. 
The purification procedure proved to be cumbersome and 
time-consuming. The yield was insufficient in terms of re-
covery and purity to allow a successful immunization of rab-
bits and further characterization. Therefore, an improved 
method for the isolation of AFBP from preterm AF was devel-
oped, with high speed gel filtration chromatography (HSGFC) 
and disc-gel electrophoresis as the final steps (chapter III). 
Details about the methodology of HSGFC are presented in ap-
pendix 1, chapter III. Purified AFBP migrated in analyti-
cal polyacrylamide gel electrophoresis systems as a single 
band ~Nith an apparent molecular weight of 35-40,000. AFBP 
probably is a glycoprotein, since it is recovered from a 
Concanavalin A column. Therefore, the molecular weight de-
termination may be subject to error. The multiple bands, 
foUnd during analytical polyacrylamide ampholine isoelec-
tric focusing at pH 4.7-4.9, may represent heterogeneity 
in the degree of glycosylation of the AFBP molecule. As 
outlined in appendix 2, chapter III, the SM binding activ-
ity is heat-stable, irrespective of the hydrogen ion con-
centration. Thusfar, the final yield of purified AFBP was 
insufficient to allow either aminoacid analysis or sedi-
mentation and equilibrium analysis by analytical ultracen-
trifugation. 
There are various reasons for the limited yield. The AFBP 
content in preterm AF, in terms of microgram protein, is 
probably very low. The high SM binding activity found in pre-
term AF results from the high binding capacity of AFBP, as 
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preliminary competitive binding studies with labeled IGF-I 
and IGF-II indicate (kindly performed by H.J. Guyda, Mon-
treal, and A.J. D 1 Ercole, Chapel Hill). The substantial los-
ses can be accounted for by shoulder fractions and trailing. 
Although SM binding activity and immunoreactivity (see be-
low) of partially purified AFBP are maintained following 
acid treatment and heating procedures at various pH levels, 
molecular instability in protein (HSA) depleted conditions 
is not ruled out. Also, nonspecific attachment of AFBP to 
tubing and glassware during the last purification steps is 
likely to be a cause of protein loss. 
However, sufficient purified AFBP was obtained to immu-
nize two rabbits. An antibody was raised in one rabbit 
(chapter IV). The antiserum was cleared of anti-albumin 
antibodies by affinity-chromatography. Monospecificity was 
suggested by the lack of cross-reactivity of a limited num-
ber of proteins, among which HSA, a-fetoprotein and some 
glycoproteins. Furthermore, immunoelectrophoresis of con-
centrated preterm AF and fetal serum in the presence of 
the antibody resulted in one precipitin line (silver stain-
ing). 
The generation of a highly specific antibody directed 
against AFBP was the main initial objective of this study. 
Purification, quanti tation as well as the study of ontoge-
ny, of homology with known SM binding proteins and of bio-
logical behavior would all be greatly facilitated by the 
availability of such an antibody. At present, the antibody 
is used for final purification of AFBP by affinity-chroma-
tography (study in progress). 
A double antibody radioimmunoassay was developed. Puri-
fied AFBP was iodinated by the chloramine-T method,and di-
lutions of partially purified AFBP were designated as the 
standard, with the results expressed in ~g equivalent pro-
tein/ml. The sensitivity of the assay was improved by adop-
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tion of the nonequilibrium procedure. AFBP values were 
twice as high in preterm AF (gestational age of 16-22 
weeks) as in term AF (38-42 weeks). As SM binding activity 
in AF, determined at different gestational ages, correlated 
with fetal renal maturation, AFBP was suggested to be pres-
ent in serum (Chochinov et al., 1976; Drop et al., 1979). 
This was confirmed by measuring fractions of Sephadex G-200 
chromatographed pre- and postnatal serum by AFBP-RIA. Ac-
tivity eluted only at a volume corresponding to a molecular 
size of 35-40,000, identical to the elution volume of label-
ed AFBP. In addition, AFBP was found in urine of preterm in-
fants. It is of specific interest that no AFBP-RIA activity 
was discovered in the large molecular weight range in serum, 
chromatographed either at neutral pH (7.4) or under protein 
dissociating conditions (pH 1-2). Fraction values generally 
were higher when serum had been acidified. Thus the AFBP-
antibody dit not recognize the 150-200,000 MW SM binding 
proteins. The possibility, however, that AFBP and the 150-
200,000 MW BP are related, has not been ruled out. When 
labeled SM and serum SM binding proteins were subjected to 
cross-linking procedures, followed by polyacrylamide gel 
electrophoresis, several bands, including one of 38,000 MW, 
were found. The AFBP-antibody will be used to determine AFBP 
antigenicity of the bands (study in progress in collabora-
tion with A.J. D'Ercole, Chapel Hill). By measuring SM and 
SM binding activity in the individual fractions, we could 
confirm the observation by D'Ercole that at neutral pH the 
elution patterns of IGF-I/SM-C in fetal and cord serum dif-
fer (D'Ercole et al., 1980). In fetal serum of infants of 
less than 27 weeks of gestation, IGF-I/SM-C elutes at an 
apparent molecular weight of 40,000, whereas in cord serum 
the predominant elution occurs at a molecular weight of 
150-200,000. Thus, with gestation progressing, the predomi-
nant form,in which SM circulates in ~lasma, changes from an 
apparent molecular weight of 40,000 to 150-200,000, the 
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same found in normal adult sera. The !50-200,000 MW SM bind-
ing protein is believed to be under GH control, since SM 
binding and SM activity of 150-200,000 MW are diminished in 
serum of GH-deficient patients and restored when GH is re-
placed (Zapf et al., 1978; Copeland et al., 1980; White et 
al., 1981; Schalch et al., 1982). GH is present in signifi-
cant concentrations in human fetal serum at 7-10 weeks of 
gestation (Gluckman et al., 1980). The absence of the 150,000 
MW SM binding protein in mid gestation fetal serum might 
reflect fetal GH resistance o~more likely, immaturity_ of 
the mechanisms, involved in the synthesis of SM binding 
proteins (D'Ercole et al., 1980). 
Sara measured SM activity in human serum by radiore-
ceptorassay, utilizing human fetal brain plasma membrane 
as matrix (Sara et al., 1981). Levels in fetal serum were 
found to be increased, not only compared with adult values, 
but also with SM values measured by RIA. On the basis of 
this discrepancy between SM values measured in fetal 
serum by RRA and RIA, it was postulated that in the hu-
man fetus an embryonic form of SM exists. At the end of 
the first half of gestation,this embryonic SM is present 
at high concentrations. During the second half of gesta-
tion, the values gradually fall as adult forms of SM begin 
being produced. However, in this study whole serum was 
tested and fetal serum was not subjected to another RRA. 
In chapter IV,the demonstration of substantial quantities 
of SM binding activity in fetal serum is presented. There-
fore, the discrepancy between RRA and RIA SM values in fe-
tal serum can be fully explained by interference in the 
RRA of SM binding proteins, such as AFBP, leading to spu-
riously high values. 
Several recent observations in the rat have suggested a 
possible role for IGF-II in fetal growth. IGF-II levels 
are 20-lOOfold higher in fetal rat serum than in maternal 
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serum and decline within days after birth (Moses et al., 
1980). IGF-I exhibits the reciprocal developmental pat~ern: 
low values in the early neonate, rising to adult levels by 
approximately 4 weeks of age (Daughaday et al., 1982b). 
This thesis study confirms that IGF-I values in human fetal 
serum are low. IGF-II values in fetal serum determined by 
RIA have not been reported on. However, in fetal or cord 
serum, decreased SM activity has been found, determined by 
various bioassays and radioreceptorassays in which IGF-II 
is reactive (Goodyer, 1981). Thus the question of the iden-
tity of fetal SH remains unresolved. The presence of large 
quantities of a specific SM binding protein (AFBP) in fetal 
serum is an additional indication that SM plays a physiolog-
ical role during fetal growth. 
As AFBP was detectable as one peak in fractions of pre-
and postnatal serum following Sephadex G-200 chromatography, 
the AFBP-RIA was adapted in order to measure AFBP directly 
in native serum or plasma (chapter V). The dilution curve 
of native serum,at dilutions of 1:20 and up,ran parallel 
to that of the standard series to which 100 vl of a 1% so-
lution of bovine serum had been added. Quite interesting 
was the observation that acid treatment of serum results in 
an improvement of parallelism at low dilutions. Further-
more, AFBP values generally were higher in acid-treated 
ser_um than in the same untreated sample. Acid treatment 
of Cohn fraction IV or serum (human, rat) shifted recovered 
SM binding proteins from 150,000 to approximately 40-60,000 
MW forms (Hintz and Liu, 1980; Moses et al., 1979). Furla-
netto (1980) reported on an acid-stable,40,000 dalton sub-
unit of the 150,000 MW SM binding protein. It is rather 
tempting to speculate that the AFBP-antibody recognizes 
these 40-60,000 MW subunits. 
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The AFBP serum concentration appears to be influenced 
by several factors. First of all, AFBP values vary during 
the day, suggesting the presence of a circadian rhythm sen-
sitive regulatory mechanism, operative for pituitary hor-
mones. A practical consequence is that comparison of serum 
concentrations is only useful if the time of sampling is 
known. SM values vary little throughout the day, although 
a decline of serum SM-C concentrations after the onset of 
sleep has been reported (Minuto et al., 1981). 
Secondly, with the increase of age,AFBP values in pre- and 
postnatal serum show a gradual decline. The opposite holds 
true for SM values. This phenomenon remains unexplained. It 
has been estimated that less than 1% of SM circulates free 
of its carrier protein complex in serum (Zapf et al., 1980). 
The vast majority is bound to its binding proteins. In gen-
eral, therefore, total SM is measured, following acid 
treatment or an extraction procedure in order to strip SM 
from its binding proteins. Similar to the change of serum 
thyroxine and cortisol concentrations reflecting thyroxine-
binding globulin and cortisol-binding globulin content, a 
parallel shift of SM and AFBP concentrations would be ex-
pected. The unknown factor remains the quantitation of the 
150-200,000 M\~ binding proteins. 
Thirdly, the results of sex-steroid treatment of adoles-
cents with tall stature suggest that AFBP values increase 
during estrogen treatment and decline during androgen 
treatment, a phenomenon well-known for several plasma pro-
teins1such as sex-hormone binding globulin and ceruloplas-
min. 
Finally, an important observation was that AFBP values 
were significantly higher in patients with GH deficiency 
than in age-matched controls. As expected, GH treatment 
resulted in a rise of SM values. However, preliminary data 
indicate that AFBP values decline. Hintz described a simi-
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lar paradoxical correlation between a nonsaturated, acid-
stable SM binding protein with an apparent molecular weight 
of 40,000 and SM-C values before and after GH treatment of 
GH-deficient patients (Hintz et al., 1981). It is of specif-
ic interest to note that the large molecular weight SMBP 
is GH-dependent, in that low 150-200,000 MW binding activi-
ty in serum of GH-deficient patients increases to normal 
during GH treatment {Zap£ et al., 1978; Copeland et al., 
1980; White et al., 1981; Schalch et al., 1982). The corre-
lation between GH, SM and its binding protein values in se-
rum of patients with GH deficiency and other growth-related 
~isorders will be the subject of further intensive study. 
The liver is most likely the main site of production of 
SM binding proteins {Binoux et al., 1982). No active AFBP 
production could be demonstrated in cell cultures of pre-
term and term placentae. In supernatant of a hepatoma cell 
line in culture, immunoreactive AFBP was readily detectable. 
Moses reported on a human hepatoma cell line (HEP G2) se-
cretina larqe quantities of a specific SM carrier protein 
(30-50,000 ·MW) into serum-free medium (Moses et al., 1983). 
Of particular interest will be in vitro studies of the mech-
anisms through which various hormones (or patient sera) 
influence the synthesis and release of AFBP in the human 
hepatoma cell line system. 
Whereas somatomedin-ljke oeptides, isolated from human 
and various animal sources, cross-react in their respective 
detection systems, notably radioreCeptorassays and radio-
irnmunoassays, the immunoreactivity of AFBP appears to be 
species-specific, since of the animal sera tested only se-
rum of the orang-outang reacted. 
Thusfar, the physiological role of the SM binding pro-
teins is undefined. They prolong the serum half life of SM, 
which explains the relatively high and constant levels of 
SM in plasma as compared to those of other peptide hormones. 
138 
pituitary _____ _ 
liver _____ _ 
plasma 
capillary __ 
target \( 
tissues--(_) ~1111 -(.'fJ Q 1\ (:X) ~ fat 
cartilage fibroblast muscle tissue 
Fig. VI. 1. 
Schematic diagram of some hypothetical mechanisms involved in the 
regulation of SM, AFBP and the large MW SM binding proteins 
(SMBP), based upon data presented in chapter I, II, V (cf. fig. I.l.). 
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SM bound to binding proteins does not readily diffuse 
through the capillary walls (Meuli et al., 1978). There-
fore, the SM binding protein complex cannot compete for the 
insulin receptor site, protecting the tissues from the po-
tentially large, insulin-like effect of SM (Zapf et al., 
1979). This specifically holds true for the large molecu-
lar weight binding proteins (150-200,000 MW). It is not 
certain whether this applies to AFBP as well,for it has 
been demonstrated that particles with a molecular weight of 
up to 40,000 can leave the vascular system (Garlick et al., 
1970}. Various factors are likely to influence the binding 
characteristics of the SM-AFBP~complex, such as pH and se-
rum proteases (Chatelain et al., 1983), and the binding ki-
netics of SM at a cellular level (Rechler et al., 1980; Sa-
ra et al., 1983). Further study of these factors is called 
for in order to answer the question whether AFBl? functions 
solely as an SM inhibitor by limiting SM bioavailability. 
Alternatively 1 AFBP may provide the growing organ with high 
and constant circulating levels of SH, necessary for the 
diffusion of SN into crucial avascular tissues,such as car-
tilage (Hintz and Liu 1 1981). 
A schematic diagram of some hypothetical mechanisms, in-
volved in the regulation of SM, AFBP and the large MW SM 
binding proteins, is presented in fig. VI.l .. 
The role of Sr-1 in pre- and postnatal growth will not be 
fully understood unless the function of the SM binding pro-
teins has been clarified. The development of the AFBP-ra-
dioimmunoassay may contribute to a further elucidation of 
the physiological importance of SM and the SM binding pro-
teins in pre- and postnatal growth. 
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SAMENVATTING EN CONCLUSIES 
In dit proefschrift wordt de methode beschreven waarmee 
een somatomedine bindend eiwit uit preterrn vruchtwater ge-
zuiverd en gekarakteriseerd werd. Derhalve werd dit eiwit 
"Amniotic Fluid Binding Protein" (AFBP) genbemd. Nadat 
tegen dit eiwit een konijneantiserum bereid was, werd een 
specifieke bepalingstechniek voor AFBP volgens de radio-
immunoassay methode ontwikkeld. Daardoor werd het mogelijk 
het biologisch gedrag van dit eiwit te bestuderen. 
Het de term somatomedine (SM) wordt een groep serumei-
witten aangeduid die de groei bevorderen en de volgende 
eigenschappen bezitten: zij zijn van het groeihorrnoon af-
hankelijk en stimuleren de opnarne van sulfaat in het kraak-
been. Zij vertonen bovendien insuline-achtige kenmerken en 
versnellen de celdeling in vitro en in vivo. Tot dusver 
zijn twee eiwitten volledig gekarakteriseerd: "Insulin-like 
growth factor" (IGF) I en II. Daarnaast komen in het serum 
van mens en dier waarschijnlijk nog andere, onvolledig om-
schreven vormen voor. 
In hoofdstuk I wordt aangetoond dat er goede aanwijzin-
gen zijn dat SM een belangrijke rol bij de hormonale regu-
latie van foetale groei speelt. De aard en het werkingsme-
chanisme van foetaal SM zijn evenwel onopgehelderd. Het is 
zeer aannernelijk dat verschillende hormonen, alsmede voe-
dingsfactoren de werking van SM gedurende de foetale peri-
ode reguleren. 
In plasma kornt SM vrijwel niet in ongebonden vorrn voor, 
echter wel gebonden aan transport- of bindende eiwitten 
met een rnolecuulgewicht van ongeveer 150-200.000 en 
40-50.000. De functie van deze eiwitten is nog onduidelijk. 
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Het is denkbaar dat zij een belangrijke rol spelen bij de 
regulatie van de bioloqische werkzaarnheid van SM. 
In hoofdstuk II wordt de gedeeltelijke zuivering van 
AFBP uit preterrn vruchtwa~er beschreven. Dit eiwit bindt 
specifiek SM, zoals IGF-II, en rernt de biologische werk-
zaarnheid van SM in vitro. Het iso-electrisch punt van dit 
zuurbestendige eiwit bedraagt 4.7 en het rnolecuulgewicht 
is geschat op 35-40.000. 
In hoofdstuk III wordt uiteengezet hoe een bepalingsrne-
thode (de "charcoal binding assay" (CBA)) ontwikkeld werd 
waarrnee op een snelle en eenvoudige, zij het weinig gevoe-
lige wijze de bindende werkzaarnheid van SM aangetoond kon 
worden. Met behulp van onder andere hogedruk-vloeistof-
chrornatografie en gelelectroforese werd een zekere hoeveel-
heid gezuiverd AFBP verkregen met het doel om deze nader 
te karakteriseren en er konijnen rnee te irnrnuniseren. De 
methode van de hogedruk-vloeistof-chrornatografie wordt 
uitvoerig in appendix 1, hoofdstuk III beschreven. De op-
brengst van gezuiverd AFBP bleek onvoldoende te zijn voor 
een analytische ultracentrifugatie studie en een arninozuur-
analyse. Wel kon worden aangetoond dat AFBP een glycopro-
teine en bij een van 2 tot 8.5 varierende pH hittebestendig 
is (appendix 2, hoofdstuk III). 
In hoofdstuk IV kornt de bereiding van het AFBP antise-
rum aan de grde. Storende anti-alburnine antilichamen wer-
den d.m.v. een affiniteitschrornatografie verwijderd. Dat 
het antilichaarn specifiek tegen AFBP gericht is, bleek on-
der meer ui t irnrnunoelectroforese proeven. Met behulp van 
het AFBP antiserum werd een bepalingstechniek volgens de 
radioimmunoassay methode (RIA) uitgewerkt. Van een aantal 
serurneiwitten, zoals alburnine, a-fetoproteine en enkele 
glycoproteinen, werd aan,Jetoond dat zij geen kruisreactie 
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vertonen. 
AFBP waarden bleken tweemaal zo hoog in preterm vruchtwa-
ter (zwangerschapsduur 16-22 weken) als in a terme vrucht-
water (zwangerschapsduur 38-42 weken). 
Ook in op een Sephadex G-200 kolom gescheiden foetaal en 
postnataal serum werd AFBP aangetoond, en wel in fracties 
die met een rnolecuulgewicht van 35-40.000 overeenkornen. 
Er werden geen aanwijzingen gevonden dat het AFBP antili-
chaarn tevens de bindende eiwitten met een groat molecuul-
gewicht herkent. 
In fracties van op een kolom gescheiden foetaal en a 
terme navelstrengbloed werden SM en de bindende werkzaam-
heid van SM gemeten. Aldus kon de waarnerning van D'Ercole 
(1980) bevestigd worden dat in v66r de 27ste week van de 
zwangerschap verkregen foetaal serum de bindende werkzaam-
heid van SM met-een molecuulgewicht van+ 40.000 overeen-
kornt en in navelstrengbloed (a terrne zwangerSchap) voor-
namelijk de bindende werkzaamheid bij een molecuulgrootte 
van 150-200.000 gevonden wordt. Dit is opmerkelijk omdat 
de SM-bindende eiwitten met een molecuulge~:·Iicht van 150-
200.000 van het groeihormoon (GH) afhankelijk zijn en 
reeds zeer vroeg in de zwangerschap (7 8 -10 8 week) hoge GH 
spiegels in het serum gevonden worden. Derhalve zou er 
sprake kunnen zijn van ongevoeligheid voor GH. Waarschijn-
lijker echter is, dat pas in de loop van de zwanger~chap 
het rnechanisme dat de synthese reguleer~ tot ontwikkeling 
komt. 
Sara (1981) heeft de werkzaamheid van SM in onbehandeld 
foetaal serum van de mens bepaald waarbij zij van een ra-
dioreceptorassay (RRA) , met celmernbranen van foetale her-
sencellen als receptor, gebruik maakte. Zij constateerde 
een grate discrepantie tussen de met behulp van deze ra-
dioreceptorassay en de met een voor Sl'-1 specifieke radio-
immunoassay bepaalde waarde van SM in foetaal serum. Der-
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halve postuleerde zij dat er een embryonale vorm van SM 
bestaat die niet met de gangbare RIA .methoden , maar wel 
in de bovengenoemde RRA gemeten kan worden. 
Hoofdstuk IV toont aan dat AFBP in aanzienlijke hoe-
veelheden in foetaal serum voorkomt. Het is welbekend dat 
SH-bindende eiwitten de bepaling van Sr.:'! d.m.v. de radio-
receptorassay kunnen verstoren, aangezien zij met de re-
ceptor wedijveren om SM te binden. Daarom zou de discre-
pantie tussen de met de RRA en met de RIA gemeten spiegels 
van SM in onbehandeld foetaal serum het gevolg kunnen zijn 
van de aanwezigheid van relatief grate hoeveelheden AFBP. 
Er zijn goede aanwijzingen dat IGF-II in de rat de rol 
van foetaal SM vervult. IGF-II waarden in foetaal ratte-
serum zijn 20-100 maal hager dan in moederlijk serum en 
dalen binnen enkele dagen na de geboorte. IGF-I spiegels 
vertonen juist het omgekeerde patroon: laag bij de pasge-
borene, geleidelijk stijgend tot volwassen waarden op de 
leeftijd van 4 weken. Oak in menselijk foetaal bloed zijn 
IGF-I waarden laag. Met bioassays en radioreceptorassays 
bepaalde IGF-II gehaltes in navelstrengbloed zijn evenwel 
oak laag. 
Dus de vraag of een embryonaal SM bij de mens bestaat 
blijft vooralsnog onbeantwoord. 
In hoofdstuk V ~Norden de resultaten genoemd van een 
aantal waarnemingen die aan de hand van AFBP bepalingen 
in onbehandeld serum of plasma gedaan zijn. De verdunnings-
curve van onbehandeld serum, mits meer dan 1 : 20 verdund, 
bleek parallel te lopen aan de standaard verdunningsreeks, 
waaraan 1% runderserum toegevoegd was. Een voorbehandeling 
van het serum met HCl (0.6 M), gevolgd door neutralisatie 
met NaOH (0.6 M), verbeterde het parallellisme bij lage 
verdunning. AFBP bepalingen in met zuur behandeld serum 
waren in het algemeen hager dan in onbehandeld serum. Het 
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is reeds bekend dat zuurbehandeling van Cohn fractie IV 
of serum tot gevolg heeft dat de bindende werkzaarnheid 
van SM van een molecuulgewicht van 150-200.000 naar 40-
60.000 verschuift. Het SM-bindend eiwit met een molecuulge-
wicht van 150-200.000 bevat een zuurbestendige component 
met een molecuulgewicht van ~ 40.000. In samenwerking met 
dr. A.J. D'Ercole (Chapel Hill) zal met behulp van het 
antiserum de samenhang tussen de groot- en kleinmoleculaire 
SM-bindende eiwitten en AFBP in menselijk serum nader be-
studeerd worden. 
De concentratie van AFBP in serum wordt door verschil-
lende factoren belnvloed: 
1. AFBP serum waarden zijn 's ochtends hoger dan 's avonds. 
Dit zou erop kunnen wijzen dat er een regulatiemecha-
nisme bestaat dat aan een 24-uursritme onderhevig is 
zoals dat bijvoorbeeld voor een aantal hypofyse hor-
monen geldt. Daarentegen zijn SM serum spiegels per 
etrnaal vrij constant alhoewel een geringe daling kort 
na het inslapen waargenomen is. 
2. In pre- en postnataal serum nemen AFBP waarden met 
toenemende leeftijd af. Het omgekeerde doet zich bij 
SM spiegels voor. Een afdoende verklaring is nog niet 
voorhanden. Geschat wordt dat minder dan 1% van het 
in bloed aanwezige SM in ongebonden vorrn circuleert. 
De overige 99% is gebonden aan de bindende eiwitten. 
Daarorn wordt rneestal totaal SM gemeten, hetgeen bete-
kent dat het serum eerst met HCl behandeld of geextra-
heerd wordt zodat SM van de bindende eiwitten geschei-
den kan worden. Zoals thyroxine en cortisol concen-
traties de gehaltes van thyroxine-bindend globuline 
en cortisol-bindend globuline weerspiegelen, zo zou 
men ook een parallel beloop van SM en AFBP concentra-
ties kunnen verwachten. De ~~bekende factor blijven 
echter de bindende eiwitten met een groot molecuulge-
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wicht (150-200.000) die tot dusver niet te quantifice-
ren zijn. 
3. De resultaten van sexsteroid behandeling van adoles-
centen met een grote lengte suggereren dat AFBP waar-
den onder invloed van oestrogenen toenernen en onder 
invloed van androgenen afnemen. Ditzelfde patroon ver-
tonen ook verscheidene plasma eiwitten zeals bijvoor-
beeld het sexhormoon-bindend eiwit en ceruloplasmine. 
4. Tenslotte is de waarnerning van betekenis dat AFBP waar-
den in serum van patienten met GH-deficientie signifi-
cant hoger dan die in serum van controlepatienten van 
overeenkomstige leeftijd zijn. Er zijn voorlopige aan-
wijzingen gevonden dat AFBP serum waarden in deze pa-
tienten tijdens GH behandeling dalen, terwijl zeals 
bekend SM spiegels stijgen. Hintz (1981) heeft deze 
zelfde paradoxale correlatie tussen een onverzadigd, 
zuurbestendig, SM-bindend eiwit met een molecuulgewicht 
van 35-40.000 en SM waarden in serum van GH-deficiente 
patienten tijdens GH behandeling beschreven . In dit 
verband is het van belang op te merken dat de SM-bin-
dende eiwitten met een molecuulgewicht van 150-200.000 
van het groeihorrnoon afhankelijk zijn. Imrners,lage con-
centraties van deze eiwitten in serum van GH-deficiente 
patienten nemen toe tijdens GH behandeling. De correla-
tie tussen GH, SM en de SM-bindende eiwitten in serum 
van patienten met GH-deficientie en andere groeistoor-
nissen zal onderwerp zijn van verder intensief onder-
zoek. 
De SM-bindende eiwitten worden waarschijnlijk in de 
lever aangemaakt. In het supernatant van een hepatomacel-
lijn in kweek is AFBP aangetoond. Dit is in overeenstem-
ming met de bevindingen van Moses (1983) dat een menselijke 
hepatornacellijn een SM-bindend eiwit met een molecuulge-
wicht van + 40.000 produceert. Een interessante en belang-
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verlagen. lees verlengen 
rijke vervolgstudie zou de bestudering van het mechanisrne 
kunnen zijn waarmee verschillende hormonen of serum van 
patienten de synthese van AFBP in de menselijke hepatoma-
cellijn in vitro reguleren. 
De immunoreactiviteit van AFBP is verrnoedelijk spe-
cies-gebonden. Met behulp van de radioimmunoassay is AFBP 
alleen aantoonbaar in serum van de orang-oetang en niet 
in serum van het konijn, de rat, het varken en het rund. 
De fysiologische functie van de SM-bindende eiwitten 
is nog onduidelijk. Het staat vast dat de bindende ei-
witten de serum halfwaardetijd van SM YHUOVVHQJHQ, en dit 
verklaart waarschijnlijk de relatief hoge en constante SM 
serum spiegels in vergelijk met die van andere peptide 
hormonen. Aan de bindende eiwitten gebonden SM diffundeert 
niet door de wand van de bloedcapillairen heen. Derhalve 
kan het SM-bindend eiwitcornplex de insulinereceptor niet 
in beslag nemen en beschermt het bindend eiwit de weefsels 
tegen de mogelijk aanzienlijke insuline-achtige v;er:kzaam-
heid van Sl-1. Dit geldt zeker voor de eiwitten met een groot 
molecuulgewicht (150-200.000). Maar aangezien deeltjes 
met een molecuulgewicht tot~ 40.000 het vaatbed mogelijk 
wel kunnen verlaten, bestaat er enige tv.rijfel of dit ook 
voor AFBP opgaat. 
Nader onderzoek is nodig naar het mechanisme waardoor 
SM a an de bindende eiv.Ti tten en aan de celmembraan van het 
eindorgaan gebonden wordt. Deze studie zou een antwoord 
kunnen geven op de vraag of AFBP uitsluitend als remmer 
van de biologische werkzaarnheid van SM optreedt dan wel 
als een transporteiwit fungeert, dat het lichaam van con-
stante spiegels van circulerend SM voorziet. 
Met de ontwikkeling van een specifieke bepalingsmethode 
voor AFBP, zoals in dit proefschrift beschreven is, is qe-
149 
poogd een bijdrage te leveren aan de opheldering van de 
fysiologische betekenis van SM en de SM-bindende eiwitten 
tijdens het pre- en postnatale groeiproces. 
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